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1 INTRODUCTION 
 
Both observational and intervention studies have clearly established the important 
role of total and low density lipoprotein (LDL) cholesterol as risk factors for 
coronary heart disease (CHD) (Martin et al. 1986, The Scandinavian Simvastatin 
Survival Study Group 1994, Shepherd et al. 1995). A low level of serum high 
density lipoprotein (HDL) cholesterol is also associated with an increased risk of 
CHD (Gordon et al. 1989, Rubins et al. 1999). Growing evidence of the relationship 
between serum triglyceride (TG) concentration and CHD has accumulated in the 
1990´s (Manninen et al. 1992, The BIP Study Group 2000).  
 
Serum lipid and lipoprotein levels are determined by both genetic and 
environmental factors. Hereditary dyslipidemias may be due to single gene 
mutations as in familial hypercholesterolemia, or result from the combined effect of 
a few or several genes that may interact with each other and/or environmental 
factors. Familial combined hyperlipidemia (FCHL), the most common hereditary 
dyslipidemia, is an example of a complex lipid disorder that has a heterogeneous 
background. The current estimate of the prevalence of FCHL in Western 
populations varies between 0.3 and 2.0% (Goldstein et al. 1973, Grundy et al. 
1987), which corresponds to 15 000-100 000 FCHL patients in Finland. FCHL is 
characterised by elevated serum levels of total cholesterol (TC) and/or 
triglycerides. Despite intensive research for almost three decades, the exact 
metabolic and genetic background of FCHL still remains to be solved. 
 
Adipose tissue stores most of the body´s triglycerides and fatty acids, and FCHL is 
characterised by elevations of serum triglycerides and fatty acids. An elevated 
serum fatty acid level has several deleterious consequences: it reduces insulin 
sensitivity and increases glucose output from the liver. Increased fatty acid flux to 
the liver stimulates very low density lipoprotein (VLDL) apolipoprotein B (apoB) 
production resulting in a lipid profile typical of FCHL. In recent years adipose tissue 
has proved to be not only a passive energy store, but an active endocrine organ 
that synthesises and secretes several bioactive molecules (Spiegelman and Flier 
1996). These observations have resulted in growing interest in abnormalities of 
adipose tissue metabolism as possible causes for FCHL.  
 
The aim of this work was to examine whether selected key regulators of adipose 
tissue fatty acid metabolism play a central role in the pathogenesis of FCHL. 
Should abnormalities in regulators of adipose tissue fatty acid metabolism have a 
primary role in the pathogenesis in FCHL, these defects would also be expected to 
be reflected in the degree of atherosclerosis. To quantify early atherosclerosis, 
FCHL family members were subjected to carotid artery ultrasonography with 
intima-media thickness (IMT) measurements. Ultrasonographic examination was 
also carried out to assess the validity of the lipid criteria that are currently used for 
categorising the FCHL family members as affected or unaffected. Finnish FCHL 
families that were identified and carefully characterised as a part of the European 
multicenter study on familial dyslipidaemias in patients with premature coronary 
heart disease (EUFAM Study) provided unique material for this work. 
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2 REVIEW OF THE LITERATURE 
 
2.1 Familial combined hyperlipidemia 
 
Familial combined hyperlipidemia is the most common hereditary lipid disorder 
among patients with premature CHD. FCHL was first characterised in 1973 when 
Nikkilä and Aro (1973) described 101 patients who had survived myocardial 
infarction under the age of 50 years. They observed that in 24 (24%) of the 101 
families, half of the family members were hyperlipidemic, and represented different 
lipid phenotypes, i.e. multiple type hyperlipidemia. Shortly after this report, 
Goldstein et al. (1973) reported a similar dyslipidemia they called familial combined 
hyperlipidemia, in 47 (27%) of 176 families of hyperlipidemic survivors of 
myocardial infarction under 60 years of age. The third group to characterise FCHL 
independently (in 1973) was Rose and co-workers (1973), who also considered the 
features associated with this lipid abnormality: obesity, impaired glucose tolerance 
and hyperuricemia. Genest et al. (1992) showed later that 14% of survivors of 
myocardial infarction below the age of 60 have FCHL. Estimates on the population 
prevalence of FCHL vary between 0.3 and 2.0% (Goldstein et al. 1973, Grundy et 
al. 1987), while 10-20% of patients with early-onset CHD may suffer from FCHL 
(Goldstein et al. 1973, Nikkilä and Aro 1973, Grundy et al. 1987, Genest et al. 
1992). 
 
2.1.1 Diagnostic criteria 
 
FCHL diagnosis is still based on examination of whole families. FCHL diagnosis 
requires presence of different lipid phenotypes in affected first-degree relatives: 
elevated serum total cholesterol (Fredrickson´s lipid phenotype IIA), triglycerides 
(lipid phenotype IV), or both (combined lipid phenotype IIB) (Goldstein et al. 1973, 
Nikkilä and Aro 1973, Rose et al. 1973, Grundy et al. 1987). The lipid cut-off points 
used to define the phenotypes usually utilise age and gender-specific 90th or 95th 
population percentiles of TC and TG (Cullen et al. 1994, Bredie et al. 1996, Porkka 
et al. 1997). When the 90th age and gender-specific percentiles for TC and TG 
were used in Finnish FCHL families, 45% of family members were categorised as 
affected. If the 95th percentiles were utilised, only 20% of family members were 
affected (Porkka et al. 1997). In some studies lower percentiles have been used, 
or the definition has been based only, or in part, on reference values of TC and TG 
(Castro Cabezas et al. 1993b, Reymer et al. 1995, Karjalainen et al. 1998). The 
differences in diagnostic criteria are further accentuated by the use of serum apoB 
or LDL cholesterol as criteria (Castro Cabezas et al. 1993b, Ascaso et al. 1998). 
The existence of premature CHD in the family is also often required for FCHL 
diagnosis in addition to the lipid criteria (Castro Cabezas et al. 1993b, Reymer et 
al. 1995, Porkka et al. 1997). 
 
2.1.2 Other characteristics 
 
2.1.2.1 Elevation of apoB-containing particles  
 
Elevations of serum TC and TG in FCHL are reflected in lipoproteins as an 
increased number of both VLDL and LDL particles. Since each of these particles 
contains one molecule of apoB, an increase in serum concentration of apoB is a 
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frequent finding in FCHL patients (Brunzell et al. 1983, Kwiterovich et al. 1987, 
Austin et al. 1990a, Genest et al. 1992). A high serum level of apoB is also a 
characteristic feature of hyperapobetalipoproteinemia (hyperapoB). The term 
hyperapoB was initially applied to conditions characterised by high levels of LDL 
apoB with normal levels of LDL cholesterol (Sniderman et al. 1980, Sniderman et 
al. 1982). As hyperapoB also predisposes patients to premature CHD (Sniderman 
et al. 1980, Sniderman et al. 1982, Kukita et al. 1985, Kwiterovich et al. 1993) and 
aggregates in families (Sniderman et al. 1985, Coresh et al. 1993), it is still not 
known whether these are two distinct entities or two overlapping syndromes 
(Grundy et al. 1987, Sniderman et al. 1992).  
 
2.1.2.2 Small dense LDL 
 
A tendency towards smaller and denser LDL particles in FCHL has been observed 
by several authors (Austin et al. 1990a, Hokanson et al. 1995, Bredie et al. 1996). 
Small, dense LDL particles are associated especially with high serum TG levels 
(McNamara et al. 1987, Austin et al. 1988, Austin et al. 1990b), and are thus 
particularly prevalent in subjects with lipid phenotypes IIB and IV. In the study by 
Austin et al. (1990a) FCHL family members with small and dense LDL particles 
also exhibited significantly lowered HDL cholesterol in addition to elevated plasma 
levels of apoB and TG. 
 
The propensity towards smaller and denser LDL particles, which are prone to 
oxidation (Chait et al. 1993, Dejager et al. 1993, de Rijke et al. 1997), and show 
decreased binding affinity to LDL receptors (Galeano et al. 1994, Toyota et al. 
1999) and increased binding to arterial wall proteoglycans (Anber et al. 1996), may 
in part explain the increased risk of CHD in FCHL (Austin et al. 1988, Lamarche et 
al. 1997).  
 
2.1.2.3 Exaggerated postprandial hyperlipemia 
 
Dietary fat is packed by intestinal enterocytes into chylomicrons. These large, TG-
rich particles are secreted into the lymphatic system, from which they enter the 
venous circulation. The apoB-48 produced by enterocytes is the structural protein 
in chylomicrons. Other surface apoproteins of chylomicrons are A-I, A-IV, C-II, C-III 
and E (Gotto et al. 1986). 
 
Several studies have shown that FCHL is associated with exaggerated 
postprandial lipemia. Castro Cabezas and co-workers (1993a, 1993c) have 
demonstrated delayed chylomicron and chylomicron remnant clearance in FCHL 
patients. When serum TG levels were lowered by drug treatment, chylomicron 
clearance improved, but did not return to the level of the controls (Castro Cabezas 
et al. 1993a). In a later study by the same authors the postprandial responses of 
apoB-100 and apoB-48 were measured separately to distinguish between 
lipoproteins of hepatic and intestinal origins (Castro Cabezas et al. 1994). ApoB-48 
concentrations remained elevated compared with apoB-100 levels, suggesting that 
the exaggerated postprandial lipemia in FCHL is due to both overproduction of 
VLDL and defective clearance of TG-rich lipoproteins. 
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2.1.2.4 Insulin resistance and glucose intolerance 
 
FCHL patients, especially if they are hypertriglyceridemic, often present with 
hyperinsulinemia, dependent on, or independent of, obesity (Hunt et al. 1989, 
Castro Cabezas et al. 1993b, Vakkilainen et al. 1998, Pihlajamäki et al. 2000a). 
Vakkilainen et al. (1998) showed that affected FCHL family members have 
impaired glucose tolerance compared with their unaffected relatives. This 
difference was also found in men, but not in women, with lipid phenotype IIA. A 
similar finding was reported by Ascaso et al. (1998) when results of the oral 
glucose tolerance test (OGTT) were compared between FCHL subjects and body 
mass index (BMI) matched normolipidemic control subjects.  
 
Insulin resistance is associated with most of the typical features of FCHL: elevated 
serum TG, low HDL cholesterol and small, dense LDL particles (Reaven 1988, 
Byrne et al. 1994, Taskinen 1995). Insulin resistance in FCHL has been 
demonstrated in several studies using either the minimal model (Ascaso et al. 
1998) or euglycemic clamp (Aitman et al. 1997, Bredie et al. 1997b, Karjalainen et 
al. 1998).  
 
Impaired insulin action in FCHL has been shown to affect not only glucose uptake, 
but also the regulation of free fatty acid (FFA) metabolism (Aitman et al. 1997, 
Karjalainen et al. 1998). Karjalainen et al. (1998) performed euglycemic clamp on 
58 FCHL family members and 72 control subjects. The suppression of FFA during 
hyperinsulinemia was impaired in all affected FCHL family members compared 
with controls. Importantly, a similar defect in FFA suppression was also seen in 
unaffected FCHL family members without hyperlipidemia. The result was later 
confirmed by the same group in 55 affected and 50 unaffected FCHL family 
members (Pihlajamäki et al. 2000a). Elevated fasting and postprandial FFA levels 
in FCHL have been previously reported by Castro Cabezas et al. (1993b). 
 
2.1.3 Genetics of familial combined hyperlipidemia 
 
When FCHL was first described in 1973 by three independent groups, Goldstein et 
al. (1973) suggested transmission of the FCHL trait by a single, autosomal 
dominant gene, whereas Nikkilä and Aro (1973) proposed a heterogeneous origin 
for this disorder. Further studies have suggested major genes acting on serum TG 
(Cullen et al. 1994), apoB (Jarvik et al. 1994, Bredie et al. 1997a), and LDL particle 
size (Bredie et al. 1996), or both apoB and LDL particle size (Juo et al. 1998). 
 
Lipoprotein lipase (LPL) is one of the most extensively studied candidate genes in 
FCHL. Babirak et al. (1992) reported that up to a third of subjects with FCHL have 
reduced LPL activity associated with elevated serum TG and low HDL cholesterol. 
Several studies have established that LPL mutations do not represent a frequent 
cause for FCHL (Gagné et al. 1994, Nevin et al. 1994, Yang et al. 1995, Pajukanta 
et al. 1997), even if mutations in the LPL gene are able to modify plasma lipid 
levels in subjects with FCHL (Reymer et al. 1995, de Bruin et al. 1996, Hoffer et al. 
1996, Hoffer et al. 1998). 
 
As regards other lipolytic enzymes, hormone-sensitive lipase (HSL) and hepatic 
lipase (HL) have been ruled out as major FCHL loci in Finnish FCHL families 
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(Pajukanta et al. 1997). However, some reports support the role of HSL and HL as 
possible susceptibility or modifier genes for FCHL (Gehrisch et al. 1999, Allayee et 
al. 2000, Pihlajamäki et al. 2000b, Pihlajamäki et al. 2001). 
 
The apoA-I/C-III/A-IV gene cluster on chromosome 11 is interesting with regard to 
FCHL because apo C-III inhibits the catabolism of TG-rich particles by LPL, and 
may thus influence serum TG levels (Ginsberg et al. 1986). An association 
between FCHL and polymorphisms in this cluster has been reported in several 
studies (Hayden et al. 1987, Wojciechowski et al. 1991, Tybjærg-Hansen et al. 
1993, Xu et al. 1994, Dallinga-Thie et al. 1996, Dallinga-Thie et al. 1997, Ribalta et 
al. 1997, Groenendijk et al. 1999). However, no association between the gene 
cluster and FCHL was found in two studies, including the Finnish FCHL study 
(Marcil et al. 1996, Tahvanainen et al. 1998). Linkage studies on FCHL and the 
apoA-I/C-III/A-IV gene cluster have also produced conflicting results 
(Wojciechowski et al. 1991, Xu et al. 1994, Dallinga-Thie et al. 1997, Allayee et al. 
1998, Wijsman et al. 1998). Recently, new genetic variants in apoA-I and apoC-III 
genes have been shown to be associated with plasma TG and apoC-III levels 
(Groenendijk et al. 2001). Moreover, specific haplotype combinations of these two 
variants were associated with elevated lipid levels in probands and spouses 
(Groenendijk et al. 2001). 
 
Among other interesting loci identified recently are the lecithin:cholesterol 
acyltransferase and manganese superoxide dismutase (an enzyme affecting 
lipoprotein oxidation and possibly formation of small, dense LDL particles) loci 
(Aouizerat et al. 1999a). Polymorphisms in genes encoding intestinal fatty acid 
binding protein, β3-adrenergic receptor and peroxisome proliferator-activated 
receptor (PPAR) -γ2 have been shown to modify lipid metabolism and insulin 
sensitivity in Finnish FCHL families, but none of these genes was likely to 
represent a major FCHL locus (Pihlajamäki et al. 1997, Pihlajamäki et al. 1998, 
Pihlajamäki et al. 2000c).  
 
The first novel FCHL locus on chromosome 1q21-q23 was recently revealed by 
Pajukanta and co-workers in Finnish FCHL families (Pajukanta et al. 1998). This 
study emphasised the combined lipid phenotype as a diagnostic criterion. The 
linkage to chromosome 1 was later replicated in 12 Chinese and 24 German FCHL 
families (Pei et al. 2000), and 71 FCHL families of the Family Heart Study in the 
United States (Coon et al. 2000). The locus probably represents a novel, so far 
unknown gene. Aouizerat and co-workers (Aouizerat et al. 1999b) have reported a 
novel FCHL locus on chromosome 11 in Dutch FCHL families. 
 
Four additional putative loci that influence serum TG (chromosomes 10 and 2), TC 
(chromosome 10), and apoB (chromosome 21) in FCHL have been suggested by 
Pajukanta et al. (Pajukanta et al. 1999).  
 
Despite rapid technical advances in molecular genetics, dissecting the genetic 
basis of FCHL has proved extremely complicated. Nikkilä and Aro (1973) were 
remarkably farsighted in predicting, as long ago as 1973, that ”probably this 
disorder will appear to be heterogeneous”, and that ”it possibly represents a 
polymorphic expression of several genotypes”. Differences in diagnostic criteria 
(see chapter 2.1.1), uncertainty of the penetrance, and population differences have 
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in part prevented identification of the underlying genetic defects. Recognition of 
gene-environment and gene-gene interactions further complicates the elucidation 
of the genetic background of this complex disease.  
 
 
2.2 Metabolic disturbances in familial combined hyperlipemia 
 
Two main hypotheses that aim to explain the pathophysiology of FCHL are 
depicted in Figure 1. Below, numbers in parentheses refer to Figure 1. One 
concept considers the increased secretion of apoB-100-containing lipoproteins 
from the liver (1), with or without impaired clearance of triglycerides, the primary 
metabolic defect. The delayed clearance of TG-rich particles may be due to 
defective lipolysis of the TG-rich particles (2), and/or impaired uptake of remnant 
particles (3). The other hypothesis states that disturbances in adipose tissue 
metabolism - either reduced fatty acid uptake (4) or increased fatty acid 
mobilisation from adipose tissue (5) - are the initial metabolic perturbations that 
secondarily lead to overproduction of VLDL apoB.  
 
2.2.1 Increased production of apoB-containing particles in the liver 
 
Most kinetic studies have supported the concept that elevated serum apoB and TG 
levels in FCHL are due to abnormally high VLDL apoB production rate in the liver 
(Chait et al. 1980, Janus et al. 1980, Kissebah et al. 1981, Teng et al. 1986, 
Cortner et al. 1991, Venkatesan et al. 1993, Cuchel et al. 1997). In a study by 
Kissebah et al. (1984) LDL apoB synthesis remained elevated even after 
normalisation of plasma lipid levels by diet and fibrate treatment. 
 
The hydrophobic lipid core of VLDL particles contains triglycerides and cholesteryl 
esters, surrounded by a hydrophilic surface layer of phospholipids, non-esterified 
cholesterol, and apolipoproteins C-I, C-II, C-III, E, and one molecule of apoB-100. 
ApoB-100 is essential for the assembly and secretion of VLDL. In normal subjects, 
more than 90% of apoB-100 is secreted in VLDL, whereas secretion to 
intermediate density lipoproteins (IDL) and LDL is increased in familial 
hypercholesterolemia (Fisher et al. 1991). ApoB gene expression does not vary 
widely even when secretion of apoB from liver cells in vitro changes markedly 
(Pullinger et al. 1989, Ginsberg 1995). The rate at which apoB-containing particles 
are secreted depends mostly on the proportion of apoB that is protected from post-
translational degradation (Boren et al. 1993b, Wu et al. 1994). The ability of apoB 
to assemble a large enough lipid core determines whether it will be able to 
translocate and be secreted as a mature particle (Dixon et al. 1991, Boren et al. 
1993a). Thus, protection against proteolysis is critically dependent on the 
availability of TG. There is evidence that other lipid components, cholesterol 
(Fungwe et al. 1992) and cholesteryl esters (Cianflone et al. 1990b, Cianflone et al. 
1992), can also influence apoB and VLDL secretion, but the data are to some 
degree conflicting (Dashti 1992, Wu et al. 1994).  
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Figure 1. Schematic illustration of the hypotheses aiming to explain the metabolic abnormalities in FCHL. See text (chapter 
2.2) for explanation. CHYLO denotes chylomicrons; CHYLO-remnant, chylomicron remnants; LRP, LDL receptor-related 
protein and LDL-R, LDL receptor. 
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Microsomal transfer protein (MTP) protects apoB from degradation by transferring 
core lipids, TG and cholesteryl esters to the translocating apoB peptide (Pan et al. 
2000) (Figure 2). Cultured cells from subjects with abetalipoproteinemia lack MTP, 
and translocation of apoB is arrested (Du et al. 1996).  
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Figure 2. Schematic illustration of VLDL production and intravascular metabolism of TG-
rich particles. See text (chapter 2.2.1) for explanation. FA, fatty acid; CE, cholesteryl ester; 
PL, phospholipid; Chylo, chylomicron; LDL-R, LDL receptor and LRP, LDL receptor-related 
protein. 
 
 
 
2.2.1.1 Effect of fatty acids on VLDL apoB production 
 
As discussed above, VLDL secretion is largely determined by the availability of its 
substrates, of which fatty acids appear to be the most important. Fatty acids for 
VLDL synthesis can originate from different sources: from lipoprotein remnants 
returned to the liver or from plasma non-esterified fatty acids, or they can be 
synthesised de novo (Gibbons and Wiggins 1995, Lewis 1997) (Figure 2). De novo 
synthesis of fatty acids appears to account for only a minor proportion of newly 
synthesised VLDL TG (Hellerstein et al. 1991, Aarsland et al. 1996). Non-esterified 
fatty acids delivered to the liver are not directly utilised for VLDL assembly, but also 
first enter the cytoplasmic TG pool. Most (up to 70%) VLDL TG origins from this 
cytoplasmic store, and undergoes lipolysis before re-esterification of fatty acids.  
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When Lewis and co-workers (1995) infused both heparin and Intralipid to induce an 
increase in plasma FFA in eight healthy males, they observed that elevation of 
plasma FFA in vivo acutely stimulates VLDL apoB production. Several authors have 
established that when oleic acid is added to HepG2 cell culture medium, both TG 
and apoB synthesis increase (Pullinger et al. 1989, Cianflone et al. 1990b, Dixon et 
al. 1991, Byrne et al. 1992, Wu et al. 1994). As the number of lipoprotein particles 
secreted from the liver is comparable to the amount of apoB that is secreted, VLDL 
production increases accordingly.  
 
2.2.1.2 Effect of insulin on VLDL apoB production 
 
The association between chronic hyperinsulinemia and increased VLDL production 
in vivo has been well described in both humans and animals (Reaven et al. 1981, 
Tobey et al. 1981, Steiner et al. 1984). Lewis (1997) stated in his review article that 
chronic insulin exposure may reduce fatty acid oxidation and stimulate TG 
esterification, and thus enhance de novo lipogenesis in spite of reduced FFA flux to 
the liver. On the other hand, acute hyperinsulinemia suppresses VLDL TG and 
VLDL apoB production. The evidence is derived from studies both in vitro 
(Durrington et al. 1982, Byrne et al. 1991) and in vivo in healthy subjects (Vogelberg 
et al. 1980, Lewis et al. 1994, Lewis et al. 1995, Malmström et al. 1997).  
 
Insulin affects VLDL production primarily by limiting the availability of FFA. Insulin 
inhibits the action of HSL, which is the key lipolytic enzyme that mobilises fatty acids 
from adipose tissue. Recently, Malmström et al. (1998) studied whether insulin has 
a direct effect on VLDL production. VLDL apoB production was determined in 
healthy men during infusion of acipimox, an antilipolytic agent, or insulin. Only 
insulin suppressed the net production of VLDL apoB. Acipimox lowered the 
production of larger TG-rich VLDL1 particles, but at the same time the production of 
smaller VLDL2 particles was increased. The net VLDL production remained 
constant. They concluded that there is an insulin-dependent mechanism, other than 
FFA suppression, that affects VLDL production. Similar results have been reported 
by Lewis et al. (1995) in healthy male volunteers. Insulin-resistant individuals have 
been found to be resistant to the acute suppressive effect of insulin on VLDL 
production, despite a reduction in plasma FFA (Lewis et al. 1993, Malmström et al. 
1997). However, the specific mechanisms by which insulin directly affects VLDL 
production are currently unknown.  
 
2.2.2 Intravascular metabolism of triglyceride-rich lipoproteins 
 
In the circulation, large VLDL1 particles are converted stepwise into smaller VLDL2, 
IDL and LDL particles. LPL, HL, and cholesterol ester transfer protein (CETP) have 
critical and complementary functions in the delipidation cascade (Figure 2). 
 
LPL is the key enzyme in removing lipoprotein TG from circulation (Eckel 1989). 
LPL resides on the luminal side of endothelial cells, where it is bound to 
proteoglycans (Olivecrona and Bengtsson-Olivecrona 1990). LPL hydrolyses TG in 
chylomicrons and VLDL particles to monoglycerides and FFA, and thus converts 
VLDL into IDL. One third of FCHL patients may have reduced LPL activity (Babirak 
et al. 1992). Individuals heterozygous for LPL deficiency have reduced LPL activity 
and mass, and their lipid phenotype resembles that of FCHL (Babirak et al. 1989). 
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However, Olivecrona and Olivecrona (1995) concluded in their review article that 
most LPL heterozygotes have normal lipid levels, unless exposed to another 
predisposing condition such as diabetes. 
 
HL is critical for conversion of IDL to LDL. In individuals with HL deficiency, VLDL is 
converted to IDL at a normal rate, but further conversion of IDL to LDL is 
significantly reduced (Demant et al. 1988). HL is also able to hydrolyse TG and 
phospholipids in HDL (Olivecrona and Bengtsson-Olivecrona 1990). Interestingly, 
HL seems to play a role in chylomicron and VLDL clearance by acting as a bridging 
protein to binding with LDL receptor-related protein and LDL receptor (Krapp et al. 
1996, Medh et al. 1999). LPL also enhances the binding of apoE-containing 
lipoproteins to LDL receptor-related protein (Beisiegel et al. 1991). 
 
Along the delipidation cascade, there is also exchange of lipid components between 
different lipoproteins. Plasma CETP facilitates the transfer of cholesteryl ester from 
HDL to apoB-containing lipoproteins, whereas TG are transferred from TG-rich 
particles to LDL and HDL (Fielding et al. 1995). CETP mass concentration has been 
shown to be elevated in combined hyperlipidemia (McPherson et al. 1991, Tato et 
al. 1995). However, it seems that the accelerated net transfer of neutral lipids 
observed in combined hyperlipidemia results from an increase in VLDL 
concentration, whereas CETP mass is not a major determinant of CETP activity 
(Mann et al. 1991, Guérin et al. 1996). Increased CETP activity also enhances the 
exchange of HDL cholesteryl esters for VLDL triglycerides, which in turn generates 
TG-rich HDL, which is a good substrate for plasma lipases (Ginsberg 1996).  
 
Phospholipid transfer protein (PLTP) plays a role in the transfer of phospholipids 
from TG-rich lipoproteins to HDL. PLTP may also participate in the reverse 
cholesterol transport (Lagrost et al. 1998). However, no strong evidence for a direct 
relationship between plasma PLTP and lipid levels has been offered, though in one 
study serum PLTP activity correlated with serum TG (Tahvanainen et al. 1999).  
 
2.2.3 Clearance of triglyceride-rich particles from the circulation 
 
VLDL production from the liver is increased in FCHL, as stated above. However, the 
number of apoB-containing particles in the circulation depends also on the rate of 
elimination. Aguilar-Salinas and co-workers (1997) observed decreased catabolic 
rates rather than increased production of VLDL and LDL apoB in FCHL kindred. 
Furthermore, the lipid lowering effect of pravastatin treatment in this study was due 
to an increase in the fractional catabolic rate of LDL apoB, whereas lovastatin 
therapy has been reported to reduce the production of apoB-containing lipoproteins 
(Arad et al. 1990, Cuchel et al. 1997). 
 
VLDL and lipoprotein particles originating from VLDL can be directly removed from 
the circulation at any point of the lipolytic cascade. LDL receptor removes VLDL2, 
IDL, and LDL particles from plasma, but large VLDL1 must undergo conformational 
changes during lipolysis before apoB or apoE can bind to LDL receptors. Another 
catabolic route for large VLDL particles is via LDL receptor-related protein, which 
binds apoE (Beisiegel et al. 1989). VLDL receptor binds VLDL but not LDL 
(Takahashi et al. 1992). The natural sites of high VLDL receptor expression are the 
heart, skeletal muscle and adipose tissue, where fatty acids are actively 
  
19 
metabolised (Aalto-Setälä et al. 1998). Studies on knockout mice suggest that the 
role of VLDL receptor is not essential in TG clearance from plasma, since mice 
lacking the VLDL receptor had normal plasma lipid levels even when subjected to a 
high-fat diet (Frykman et al. 1995). 
 
Intravascular lipolysis of chylomicrons results in formation of chylomicron remnants 
that reside in the same density range as VLDL remnants. In postprandial state, the 
increase in serum TG is attributed to both chylomicron and VLDL TG, the VLDL 
fraction representing about 80% of the increase in lipoprotein number (Genest et al. 
1986, Karpe et al. 1993, Schneeman et al. 1993). VLDL and chylomicrons compete 
for LPL, and since chylomicrons have greater affinity for LPL than VLDL, large 
VLDL particles accumulate in plasma postprandially when the common removal 
pathway is saturated (Karpe et al. 1993, Schneeman et al. 1993). Chylomicron 
remnants are taken up by liver parenchyma cells through the LDL receptor and LDL 
receptor-related protein, which binds apoE, but not apoB-100 (Beisiegel et al. 
1989). 
 
The association between exaggerated postprandial lipemia and CHD has been 
observed by several authors, and has been reviewed by Karpe and Hamsten 
(1995). The latter proposed that it may not be chylomicrons as such that are 
atherogenic, but their metabolism may alter other lipoproteins, i.e. reduce HDL and 
skew the distribution of LDL towards smaller and denser species. Plasma CETP 
activity is enhanced when the level of TG-rich VLDL and chylomicron particles is 
increased (Mann et al. 1991, Guérin et al. 1996). The large, TG-enriched LDL 
particles are effectively hydrolysed by HL, thus generating smaller and denser LDL 
particles (Packard et al. 1997). A similar metabolic cascade results in conversion of 
TG-enriched HDL particles into denser species that are removed from the 
circulation more rapidly. A reduction in circulating HDL compromises reverse 
cholesterol transport that would give protection against atherosclerosis (Patsch 
1998). The impaired clearance of TG-rich particles from the circulation results as 
such in a prolonged residence time of these particles in the circulation. 
Consequently, the uptake of these particles by macrophages is promoted, 
enhancing the formation of foam cells and atherosclerosis (Willnow 1997). 
 
 
2.3 Adipose tissue fatty acid metabolism 
 
Elevated serum FFA levels may result from reduced FFA uptake in peripheral 
tissues or from an increased rate of fatty acid release from adipose tissue.  
 
2.3.1 Uptake of free fatty acids by adipose tissue 
 
Most human cells are capable of taking up fatty acids, which are necessary for 
several cellular processes: as an energy source, as precursors for steroid hormones 
and intracellular messengers, and as components for biological membrane lipids. 
Significantly, FFA uptake comprises both the transportation of FFA into the cells and 
incorporation of FFA into TG. Several authors have suggested that defective FFA 
esterification into TG may be responsible for hypertriglyceridemia and hyperapoB 
(Carlson et al. 1976, Rubba 1978, Arner et al. 1982, Teng et al. 1988) . Furthermore, 
FFA uptake may affect the rate at which FFA are released from TG-rich particles in 
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the first place, since high local concentrations of fatty acids may detach LPL from 
endothelial cells (Saxena et al. 1989, Peterson et al. 1990). 
 
2.3.1.1 Fatty acid transporters  
 
It has now been shown that FFA uptake exhibits kinetic properties of both non-
facilitated and protein-facilitated transport. Three proteins have been suggested to 
mediate FFA uptake into adipocytes: plasma membrane fatty acid binding protein 
(FABP-pm) (Stremmel et al. 1985, Isola et al. 1995), fatty acid translocase (FAT) 
(Abumrad et al. 1993) and fatty acid transport protein (FATP) (Schaffer et al. 1994).  
 
Induction of FATP has been shown to increase FFA uptake in adipocyte-like 3T3-L1 
cells (Martin et al. 1997). The messenger RNA (mRNA) expression of FATP and 
FABP-pm correlated strongly with FFA uptake in adipocytes from Zucker fatty rats 
(Berk et al. 1997). An increase in FAT and FABP-pm mRNA in adipose tissue of 
ob/ob mice as compared to control littermates has been reported (Memon et al. 
1999). Acyl-CoA synthetase (ACS) catalyses activation of FFA into acyl-CoA 
derivatives, thus preventing the escape of fatty acids from the cell (Suzuki et al. 
1990). ACS mRNA levels were found to increase in parallel with FAT and FABP-pm 
mRNA in ob/ob mice, further promoting the uptake of FFA (Memon et al. 1999). On 
the other hand, FAT and FABP-pm mRNA were up-regulated in the liver of ob/ob 
mice (Memon et al. 1999), which may provide more substrates for VLDL production. 
So far, no studies on fatty acid transporters or ACS and dyslipidemia have been 
published. Fatty acid transporters and ACS will be further discussed with PPARγ in 
chapter 2.3.3.1. 
 
2.3.1.2 Effect of insulin on fatty acid uptake 
 
It is known that insulin stimulates the net uptake of FFA into adipocytes. The 
mechanisms involve suppression of HSL and stimulation of LPL. FFA ”retention” is 
enhanced by direct stimulation of re-esterification (Campbell et al. 1992, Frayn et al. 
1994). However, the effect of insulin may not be attributable to increased glucose 
uptake and glycerol-3-phosphate synthesis (Frayn et al. 1994).  
 
2.3.1.3 Acylation-stimulating protein 
 
In the late 1980s a novel regulator of FFA uptake, acylation-stimulating protein 
(ASP), was described by a group led by Sniderman and Cianflone (Cianflone et al. 
1989b). ASP is a small, 76-amino acid basic plasma protein that stimulates TG 
synthesis in vitro in human adipocytes and skin fibroblasts (Cianflone et al. 1989b, 
Baldo et al. 1993). Further purification revealed that ASP is identical to C3a-desArg 
(Baldo et al. 1993), the inactive fragment of complement anaphylatoxin C3a (Hugli 
1989). ASP is generated by interaction of three components of the alternative 
complement pathway: complement C3, factor B, and factor D (adipsin) (Baldo et al. 
1993) (Figure 3). Each of these proteins can be produced by adipocytes (Choy et 
al. 1992, White et al. 1992). Expression of adipsin is significantly down-regulated in 
rodent obesity models (Flier et al. 1987). C3 will be further discussed in chapter 
2.3.1.4.  
 
  
21 
ASP mediates its effect on TG synthesis (1) by increasing the activity of 
diacylglycerol acyltransferase, a key enzyme in TG synthesis (Yasruel et al. 1991), 
and (2) by stimulating the transport of glucose, a substrate for TG synthesis, by 
enhancing translocation of glucose transporters (GLUT 1, GLUT 3, GLUT4) to the 
cell membrane (Germinario et al. 1993, Maslowska et al. 1997b, Tao et al. 1997) 
(Figure 3). This effect is independent of, and additive to, that of insulin (Germinario 
et al. 1993). ASP has no direct effect on FFA transport across the plasma 
membrane, but stimulation of TG synthesis enhances the rate at which FFA enter 
adipocytes. In their recent report, van Harmelen and co-workers (1999) 
demonstrated that ASP may also increase the fractional re-esterification of FFA by 
stimulating phosphodiesterase 3, and to a lesser extent, phosphodiesterase 4. 
 
 
Figure 3. Simplified illustration of ASP generation and activation of the alternative 
complement pathway. C3 in circulation undergoes continuous hydrolysis into a ”C3b-like 
molecule”, C3(H2O), which differs from C3b only by its inability to bind to surfaces. In the 
fluid phase, the C3b-like molecule binds factor B. Factor D cleaves factor B into Ba and Bb, 
thereby forming a priming C3-convertase C3(H2O)Bb. C3(H2O)Bb, and later, C3bBb, 
promote cleavage of C3 into C3a and C3b. C3b can bind to surfaces. Further fate of C3b is 
determined by the nature of the surface: it is either inactivated or forms another C3 
convertase with factor B, thus initiating the amplification loop of the alternative pathway. 
ASP (C3a-desArg) is generated when plasma carboxypeptidases remove the C-terminal 
arginine from C3a. DAGT denotes diacylglycerol acyltransferase; glycerol-3-P, glycerol-3-
phosphate, and Arg, arginine. + = stimulation. 
 
 
The signalling mechanisms by which ASP mediates its effects from the plasma 
membrane have not been elucidated. Baldo et al. (1995) suggested involvement of 
the protein kinase C pathway, but this was later contradicted by van Harmelen et al. 
(1999). So far there is only indirect evidence to support the existence of the putative 
ASP receptor. Radiolabelled ASP exhibited specific saturable binding to normal and 
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hyperapoB fibroblasts (Cianflone et al. 1990a). A decrease in the cell-surface 
concentration of ASP receptors has been reported to be responsible for lowered 
ASP stimulation of TG synthesis in fibroblasts from subjects with hyperapoB and 
high plasma ASP concentration (Zhang et al. 1998). On the other hand, according 
to Kildsgaard and co-workers (1999), it is not unlikely that a highly cationic peptide 
such as ASP would bind non-specifically, in a concentration-dependent manner, to 
anionic surface molecules on fibroblasts and adipocytes. 
 
2.3.1.3.1 Acylation-stimulating protein – in vitro studies 
 
Soon after the discovery of ASP it was shown that fibroblasts from subjects with 
hyperapoB are resistant to the effects of ASP (Cianflone et al. 1990a). This was 
confirmed by Kwiterovich et al. (1990, 1994), who showed that incorporation of 
oleate into cellular TG, cholesteryl esters and phospholipids is reduced in fibroblasts 
from subjects with hyperapoB as compared with control cells. Adipocytes from 
obese subjects responded normally to ASP (Walsh et al. 1989). Maslowska et al. 
(1997a) showed that chylomicrons contain a component that stimulates ASP and 
C3 production from adipocytes. This component was later suggested to be 
transthyretin, a plasma protein associated with retinol-binding protein (Scantlebury 
et al. 1998).  
 
2.3.1.3.2 Acylation-stimulating protein – in vivo studies  
 
Cianflone and co-workers (1997) have found significantly higher fasting plasma 
ASP levels in 208 CHD patients than in 59 age-matched control subjects. There 
was a positive relation between plasma ASP and serum TG and apoB in CHD 
patients. In linear regression analysis TG, VLDL cholesterol and VLDL apoB 
contributed significantly to the variation in plasma ASP (Cianflone et al. 1997). 
Maslowska et al. (1999) determined plasma ASP concentrations in 53 morbidly 
obese (BMI > 35 kg/m2) and 183 non-obese control subjects. The median plasma 
ASP was significantly higher in obese than in non-obese subjects. In the non-obese 
subjects, ASP correlated significantly with TG and FFA, but not with BMI or apoB. In 
obese subjects, none of the variables studied correlated significantly with plasma 
ASP levels (Maslowska et al. 1999). Weyer et al. (2000) observed that plasma ASP 
was associated with percent body fat in 33 non-diabetic Pima Indians. No 
correlations between ASP and BMI, glucose, or insulin values were found, but there 
was a significant correlation between plasma ASP and serum C3. In a fat load 
study, fasting plasma ASP was associated with percent body fat, TG and FFA 
(Weyer et al. 1999). When 29 type 2 diabetic patients were treated with 
pioglitazone, glibenclamide or placebo for 6 months, the decrease in ASP correlated 
significantly with the decrease in HbA1c (Ebeling et al. 2001).  
 
Most in vivo studies on humans have focused on examining the postprandial ASP 
response. The first study was performed by Cianflone et al. (1989a) on seven 
healthy, normolipidemic subjects. They reported a sustained and significant 
increase in plasma ASP postprandially. It has since become apparent that the 
polyclonal antibody used by Cianflone and colleagues in the competitive enzyme-
linked immunosorbent assay (ELISA) detected not only ASP but also C3. The 
serum concentration of C3 is much higher than that of ASP, ranging from 0.7 to 1.4 
g/l in normal subjects, which explains why the reported plasma ASP concentrations 
  
23 
were some 1000 times higher than reported in later studies by Cianflone and 
Sniderman or other authors. Charlesworth et al. (1998) aimed to confirm the results 
of the first fat load study using radioimmunoassay (Amersham) for ASP 
measurements. They measured plasma ASP and C3 levels in eight healthy 
volunteers after a fatty meal. Six subjects were challenged with another fat meal. A 
sustained rise in plasma ASP was observed in one subject after the first meal, and 
in two subjects after the second meal. The fasting ASP concentrations averaged 
147±33 ng/ml, and those at 4 h 147±40 ng/ml. The authors concluded that despite 
substantial individual variation in postprandial ASP levels, no uniform, significant 
response in plasma ASP could be observed after the fat meals. Weyer and Pratley 
(1999) tested whether fasting and postprandial plasma ASP levels were increased 
in seven lean and eight obese Pima Indians compared to an age, sex and BMI 
matched group of Caucasians. Plasma ASP decreased in response to the fatty 
meal in all four groups with no differences between the groups.  
 
Instead of measuring ASP concentrations in peripheral plasma, Saleh et al. (1998) 
measured the veno-arterial gradient of ASP across abdominal subcutaneous 
adipose tissue in 12 subjects after an oral fat load. Sandwich ELISA was used to 
measure plasma ASP concentrations. It was demonstrated that ASP production by 
human adipose tissue in vivo is accentuated postprandially. Furthermore, the 
changes in TG clearance and fatty acid incorporation into adipose tissue followed a 
similar time course as ASP. Kalant and co-workers (2000) have more recently 
reported an increase in ASP release postprandially from subcutaneous adipose 
tissue of eight lean women, whereas in the eight obese subjects no significant 
response in ASP production was detected.  
 
C3 knockout mice, which are also necessarily ASP deficient, have provided an 
interesting tool with which to examine the role of ASP in lipid metabolism. Wetsel 
and co-workers (1999) were the first to examine the lipid profile of C3(-/-) and wild-
type mice. The average TG, cholesterol, apoB and FFA concentrations in C3(-/-) 
mice were no different from those in C3(+/+) mice. No differences in lipoprotein 
levels were observed either. Furthermore, there was no difference in postprandial 
TG and FFA levels. Contrasting results were subsequently reported by Murray et al. 
(1999) from the group of Sniderman and Cianflone. Even though no differences in 
fasting plasma lipid levels were found in C3(-/-) and C3(+/+) mice, TG clearance 
was delayed in male ASP knockout mice. Interestingly, an intraperitoneal injection 
of ASP accelerated TG clearance in male ASP-deficient mice. With regard to other 
consequences of defective FFA trapping in ASP-deficient mice, it has been reported 
that adipose tissue mass is greater in wild-type (C3+/+) than in C3(-/-) mice (Murray 
et al. 2000).  
 
2.3.1.4 Complement C3 
 
The complement system, which comprises several enzymes and regulator proteins, 
plays an essential role in infection defence and tissue injury. The protein cascade 
can be activated in two ways: the classical pathway, which involves binding of an 
antibody to complement component C1, or the alternative pathway, which is 
triggered by binding of C3 to surfaces such as microbes or cholesterol aggregates. 
An intriguing concept is the link between the complement system and adipose 
tissue biology. As discussed in chapter 2.3.1.3, complement C3 is a precursor 
  
24 
protein of ASP, and is synthesised and secreted by adipocytes (Choy et al. 1992, 
White et al. 1992). Activation of the alternative complement pathway and generation 
of ASP is depicted in Figure 3.  
 
The link between C3 and lipid metabolism is implied by the association of serum C3 
concentration with serum lipid levels. Uza et al. (1982) have reported higher serum 
C3 levels in hypertriglyceridemic subjects as compared to normolipidemic control 
subjects. Correlations between serum C3 and TC, TG, LDL cholesterol, BMI, 
systolic blood pressure (SBP), blood glucose and insulin have been detected 
(Muscari et al. 1990, Muscari et al. 1995b, Muscari et al. 1998, Muscari et al. 2000, 
Weyer et al. 2000). Serum C3 also seems to be elevated in obesity and type 2 
diabetes (Koistinen et al. 1998, Ebeling et al. 1999). 
 
The serum concentration of C3 is increased in inflammatory states such as 
systemic lupus and rheumatoid arthritis. Atherosclerosis has been suggested to be 
an inflammatory disorder, which provides an interesting link between 
atherosclerosis and C3, an acute phase protein. Complement components, 
including C3 and complement inhibitory proteins, have been isolated from human 
arterial wall (Hollander et al. 1979, Hansson et al. 1984, Vlaicu et al. 1985b, 
Niculescu et al. 1987b, Niculescu et al. 1989). As evidence that complement 
activation takes place in arterial intima, terminal complement complexes (C5b-9) 
have been localised in fibrous plaques, fatty streaks, and also in normal arterial 
intima (Vlaicu et al. 1985a, Niculescu et al. 1987a, Niculescu et al. 1987b). The 
level of complement deposition was related to the degree of atherosclerosis: more 
C5b-9 complexes were found in fibrous plaques than in fatty streaks. Seifert and co-
workers (1990) have shown that there is a lipid component in human atherosclerotic 
lesions that can activate complement. This lipid component proved not to be native 
or oxidised LDL (Seifert et al. 1990, Wieland et al. 1999). However, enzymatically 
modified LDL has been shown to activate the alternative complement pathway 
(Bhakdi 1998).  
 
Elevated serum C3 levels have been observed in subjects with peripheral 
atherosclerotic disease (Muscari et al. 1988). An association between elevated 
serum C3 and myocardial infarction has been reported both retrospectively (Muscari 
et al. 1995b) and prospectively in men (Muscari et al. 1995a). However, serum C3a 
(corresponding to C3a-desArg) levels were not increased in subjects with previous 
myocardial infarction (Muscari et al. 1995b). 
 
Two major electrophoretic variants of C3 protein, the ”fast” C3F and the ”slow” C3S, 
have been identified. These variants are inherited in an autosomal dominant 
fashion, indicating that they represent two allelic variants of the C3 gene (Barnum et 
al. 1989). The C3F allele has been found to be associated with atherosclerotic 
disease (Sörensen et al. 1975, Kristensen et al. 1978). 
 
2.3.2 Release of fatty acids from adipose tissue 
 
The primary function of adipose tissue is to store energy as triglycerides, and to 
release these energy stores as fatty acids when dietary energy substrates are 
lacking. The rate-limiting enzyme in releasing fatty acids from adipose tissue is 
hormone-sensitive lipase. Besides adipose tissue, HSL is to a lesser extent 
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expressed in muscle tissue, mammary gland, and testis in humans (Holm et al. 
2000). In rodents HSL is also expressed in pancreatic β-cells (Mulder et al. 1999). 
Alternative splicing of the HSL gene in exon 6 results in formation of a short, 
catalytically inactive human HSL protein (Laurell et al. 1997). HSL catalyses 
hydrolysis of triglycerides to diglycerides and monoglycerides. Monoglyceride lipase 
is needed to finally catalyse the breakdown of monoglycerides to glycerol and fatty 
acids. Monoglyceride lipase is not hormonally regulated, and is abundant in adipose 
tissue.  
 
2.3.2.1 Regulation of hormone-sensitive lipase activity 
 
Hormone-sensitive lipase is so called because it is regulated by hormones: 
catecholamines and insulin (Figure 4). Catecholamines are the most important 
stimulators of lipolysis. Adipocytes express three different β-adrenoreceptors: β1, β2, 
and β3, and α2-adrenoreceptors. Catecholamines stimulate lipolysis by binding to β-
receptors that are coupled to adenylyl cyclase through the GTP-sensitive Gs 
proteins. Adenylyl cyclase catalyses the formation of cyclic adenosine 
monophosphate (cAMP), which in turn activates protein kinase A, which finally 
phosphorylates the serine residues in HSL (Anthonsen et al. 1998). The main 
consequence of HSL phosphorylation has been proposed to involve translocation of 
HSL from cytosol to the surface of lipid droplets (Egan et al. 1992, Brasaemle et al. 
2000). In addition to catecholamines, thyroid-stimulating hormone, glucagon, 
cholecystokinin and parathyroid hormone can stimulate lipolysis (Arner 1996), but 
these are of minor importance. The main physiological factors that increase lipolysis 
are starvation and exercise, as reviewed by Coppack et al. (1994).  
 
Figure 4. Schematic illustration of regulation of HSL activity in adipose tissue. See text 
(chapter 2.3.2.1) for explanation. α2 denotes α2-adrenergic receptor; β1-3, β-adrenergic 
receptors 1, 2, and 3; PDE, phosphodiesterase; PKA, protein kinase A; PP, protein 
phosphatase. + = stimulation, - = inhibition. 
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Insulin is the major antilipolytic hormone. The mechanisms by which insulin inhibits 
lipolysis are not completely understood, but several mechanisms exist. Insulin 
stimulates activation of phosphodiesterase 3, which enhances cAMP degradation in 
adipocytes (Manganiello et al. 1973, Hagström-Toft et al. 1995). Exposure of human 
fat cells to insulin is followed by translocation of β-receptors to intracellular space, 
which reduces lipolytic sensitivity to β-agonists (Engfeldt et al. 1992). 
Catecholamines can also inhibit lipolysis via α2-adrenoreceptors, which inhibit 
adenylyl cyclase through the GTP-sensitive Gi proteins (Arner 1996). 
Dephosphorylation of HSL is enhanced by protein phosphatases, which can be 
stimulated by insulin (Olsson et al. 1987, Strålfors et al. 1989, Wood et al. 1993).  
 
Holm et al. (2000) recently reviewed alternative, possibly tissue-specific 
mechanisms for HSL regulation. Perilipins are a family of phosphoproteins that form 
a protective barrier on the surface of intracellular lipid droplets. A novel cytokine 
produced by adipocytes - tumour necrosis factor alpha (TNF-α) - increases lipolysis 
by lowering the level of perilipins on the surface of lipid droplets (Souza et al. 1998). 
Leptin (Wang et al. 1999) and nitric oxide (Andersson et al. 1999) have also been 
implicated in regulation of lipolysis.  
 
2.3.2.2 Regulation of hormone-sensitive lipase gene expression 
 
Glucose deprivation reduces HSL gene expression in adipocytes in vitro (Raclot et 
al. 1998). Unexpectedly, β-receptor agonists and cAMP also decrease HSL mRNA 
levels in adipocytes, which may represent a long-term counter-regulatory effect 
(Plée-Gautier et al. 1996). Neither insulin (Plée-Gautier et al. 1996) nor oleate 
(Raclot et al. 1998) influences HSL expression. TNF-α treatment has been shown to 
down-regulate HSL gene expression in 3T3-L1 cells (Sumida et al. 1990). Whether 
TNF-α also reduces HSL protein expression in vitro is not clear (Green et al. 1994, 
Rosenstock et al. 2001). To summarise, the transcriptional control of HSL is not well 
understood. HSL gene expression affects HSL activity, but it seems to have a less 
important role in the control of lipolysis than post-translational mechanisms 
(Hellström et al. 1996, Reynisdottir et al. 1998, Large et al. 1999). 
 
2.3.2.3 Effects of anatomical location and gender on lipolysis 
 
Lipolytic response to catecholamines depends on the anatomical location of the fat 
depot. Visceral adipocytes exhibit higher catecholamine-induced lipolysis than 
subcutaneous adipocytes (Östman et al. 1979, Mauriege et al. 1987, Richelsen et 
al. 1991). The clinical importance of this regional difference lies in the fact that FFA 
released from omental fat are drained by the portal vein directly to the liver. The 
different rate of lipolysis in subcutaneous and visceral adipocytes is thought to result 
from a higher number of inhibitory α2-adrenergic receptors in subcutaneous as 
compared to visceral fat (Östman et al. 1979, Mauriege et al. 1987, Richelsen et al. 
1991), whereas the number of β-receptors is increased in omental vs. 
subcutaneous adipocytes (Rebuffé-Scrive et al. 1989, Hellmer et al. 1992). 
Increased β3-receptor function, increased ability of cAMP to induce lipolysis in 
visceral fat cells (Arner 1999), and resistance to insulin-induced suppression of 
lipolysis also contribute to increased FFA release from visceral fat (Roust et al. 
1993, Meek et al. 1999). 
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2.3.2.4 Lipolysis in familial combined hyperlipidemia and insulin resistance 
 
Reynisdottir et al. (1995) examined catecholamine-activated lipolysis and HSL 
activity in 10 non-obese male FCHL patients and 22 healthy, unrelated, age and 
BMI-matched control subjects. The lipolytic response of FCHL patients compared 
with the control subjects was reduced by about 65% regardless of the level at which 
lipolysis was stimulated: catecholamine receptors, adenylyl cyclase or cAMP. HSL 
enzyme activity was 40% lower in FCHL patients than in controls. When the same 
ten FCHL subjects were later compared with another ten control subjects, a 45% 
reduction in HSL activity was observed in FCHL subjects (Reynisdottir et al. 1997). 
In another study of 15 FCHL patients and 15 control subjects, the maximum lipolytic 
capacity and HSL activity were again found to be reduced in FCHL subjects 
(Reynisdottir et al. 1998). This reduction was attributed to a 70% reduction in HSL 
protein expression, whereas there was no difference in HSL mRNA levels between 
the two groups.  
 
The effect of insulin resistance on lipolysis has been a target for several studies. A 
reduction in the number of β2-receptors, and therefore reduction in catecholamine-
stimulated lipolysis, was found in subcutaneous fat cells of elderly male subjects 
with insulin resistance (Reynisdottir et al. 1994). In another group of similar subjects 
examined by the same authors, HSL activity was not impaired in subcutaneous fat 
samples, whereas LPL activity was reduced by 43% (Reynisdottir et al. 1997). 
Recently van der Kallen et al. (2000) studied lipolysis by incubating adipocytes with 
isoprenaline or insulin. Insulin did not suppress FFA release from adipocytes 
derived from ten FCHL subjects when compared with adipocytes from subjects with 
type 2 diabetes or healthy control subjects. 
 
2.3.3 Peroxisome proliferator-activated receptor γ (PPARγ) 
 
PPARs are transcription factors belonging to a family of nuclear hormone receptors. 
Upon activation PPARs heterodimerize with the retinoid X receptor, bind to specific 
PPAR response elements (PPREs) in the promoters of their target genes, and 
enhance or suppress the transcription of these genes (Figure 5). PPARs have also 
been shown to affect gene transcription by interfering with certain signalling 
pathways in a fashion independent of DNA binding, as reviewed by Pineda Torra et 
al. (1999). The three different PPAR genes, α, γ and δ ( NUC 1, FAAR, β) have 
distinct tissue distributions. PPARα is mainly expressed in tissues with a high level 
of fatty acid oxidation: liver, muscle, kidney, heart and intestinal mucosa (Braissant 
et al. 1996, Auboeuf et al. 1997). PPARδ is ubiquitously expressed, but its 
physiological function is unknown so far (Auboeuf et al. 1997), though preliminary 
data on its influence on lipid homeostasis and reverse cholesterol transport in 
monkeys (Oliver et al. 2001) and foam cell formation in vitro (Vosper et al. 2001) 
have been presented. PPARγ comprises three different isoforms: PPARγ1, γ2 
(Fajas et al. 1997) and γ3 (Fajas et al. 1998), which are derived from the same gene 
by alternate promoter usage and different splicing. PPARγ2 protein contains 28 
additional amino acids encoded by PPARγ2 specific exon B. PPARγ1 is 
predominantly expressed in adipose tissue and the large intestine, and to a lesser 
extent in kidney, liver, small intestine, heart, spleen, monocyte/macrophages and 
other hematopoietic cells, endothelial cells and vascular smooth muscle cells 
(Greene et al. 1995, Auboeuf et al. 1997, Fajas et al. 1997, Vidal-Puig et al. 1997, 
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Marx et al. 1998a, Marx et al. 1998b, Tontonoz et al. 1998, Marx et al. 1999). Minute 
amounts (10-30 fold less than in adipose tissue) of PPARγ mRNA have been 
detected also in muscle (Fajas et al. 1997). The expression of PPARγ2 is more 
strictly confined to adipose tissue, where it represents approximately 20% of total 
PPARγ (Auboeuf et al. 1997). One study has reported the presence of PPARγ2 in 
muscle (Vidal-Puig et al. 1997). The expression of PPARγ3 transcript is directed by 
an independent promoter, and is confined to adipose tissue, macrophages and 
colon epithelium (Fajas et al. 1998, Ricote et al. 1998). PPARγ3 protein is identical 
to PPARγ1 (Fajas et al. 1998). 
 
 
Figure 5. Mechanisms of PPAR regulation. Ligand binding to E/F domain leads to binding 
of the PPAR/RXR receptor heterodimer to PPAR-response element (PPRE) of the target 
gene through the C-domain. Phosphorylation of the A/B domain by mitogen-activated 
protein (MAP) kinase down-regulates the receptor activity. The activated receptor dimer 
associates with co-factors. This involves release of co-repressor complexes and 
association with co-activator complexes that contain proteins that modulate histone 
acetylation state, and thereby open chromatin for more efficient transcription. This in turn 
facilitates target gene transcription (Spiegelman 1998, Auwerx 1999, Escher and Wahli 
2000). 
 
 
PPARγ plays a pivotal role in adipocyte differentiation. It controls the transcription of 
several central genes of energy and lipid homeostasis in adipose tissue. Recently 
PPARγ has also been reported to influence atherogenesis through its effects on 
gene expression in endothelium, smooth muscle cells and monocyte/macrophages. 
Only those functions of PPARγ that are directly related to insulin resistance and fatty 
acid and lipid metabolism will be discussed below.  
 
2.3.3.1 PPARγ in insulin resistance and fatty acid metabolism 
 
The huge interest in PPARs in recent years is due not least to the discovery that 
antidiabetic drugs of the thiazolidinedione (TZD) group are synthetic ligands of 
PPARγ (Forman et al. 1995, Lehmann et al. 1995), and that it is PPARγ that 
mediates the antidiabetic effect of TZDs (Berger et al. 1996). There are several 
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mechanisms by which PPARγ activation may improve insulin sensitivity. Adipocyte 
differentiation involves induction of several genes that are necessary for insulin 
action: insulin receptor, insulin receptor substrate-1, and glucose transporter GLUT-
4 (Cornelius et al. 1994). However, most glucose disposal takes place in muscle, 
where PPARγ is expressed only in trace amounts. It is possible that the minute 
amount of PPARγ in muscle is enough to exert its effects. The other possibility is 
that PPARγ in adipose tissue induces production of signalling molecules that affect 
insulin sensitivity in muscle and liver (Schoonjans et al. 1997). The latter option is 
supported by the observation of Chao et al. (2000) on transgenic A-ZIP mice that 
have virtually no white adipose tissue. These A-ZIP mice exhibit insulin resistance, 
hyperlipidemia and fatty liver. Treatment with rosiglitazone or troglitazone did not 
lower the glucose or insulin levels in the A-ZIP mice, suggesting that it is adipose 
tissue that is necessary for the insulin-sensitising effect of TZDs. Okuno et al. 
(1998) reported that activation of PPARγ by troglitazone induced apoptosis of large 
adipocytes in Zucker rats, potentially promoting the appearance of smaller, more 
insulin-sensitive adipocytes. 
 
Two groups of signalling molecules are generated in adipose tissue: firstly, protein 
cytokines such as leptin, TNF-α, resistin and adiponectin, and secondly, fatty acid 
derivatives. PPARγ activation reduces the expression of leptin in rat and 3T3-L1 
adipocytes (De Vos et al. 1996, Kallen et al. 1996) resulting in increased food intake 
and availability of substrates to be stored in adipocytes. This may seem illogical, but 
clinical observations in lipoatrophy and animal models have proved that a ”normal” 
amount of adipose tissue is necessary for normal glucose homeostasis (Moller and 
Flier 1991, Chao et al. 2000). There is also evidence that leptin may directly disturb 
the action of insulin in human hepatic and rat adipose cells (Cohen et al. 1996, 
Müller et al. 1997). TNF-α is known to induce insulin resistance (Hotamisligil et al. 
1994) and TZDs reduce TNF-α expression in rodents (Hofmann et al. 1994, Okuno 
et al. 1998), which possibly contributes to their insulin-sensitising effect in humans. 
Resistin is a recently discovered, adipocyte-derived signalling molecule (Steppan et 
al. 2001). Resistin expression in vivo is specific to adipose tissue, and resistin can 
be found in the serum of normal mice (Steppan et al. 2001). Steppan and co-
workers (2001) reported that serum resistin levels are elevated in animal models of 
obesity and insulin resistance, and that TZDs markedly reduce resistin gene 
expression and protein secretion (Steppan et al. 2001). However, contradictory 
results were published by Way et al. (2001). Adiponectin (AdipoQ, Acrp30 or apM-1) 
is another novel adipocytokine (Scherer et al. 1995, Hu et al. 1996b, Maeda et al. 
1996). It may provide an interesting link between obesity and vascular disease, as 
adiponectin suppresses TNF-α induced expression of adhesion molecules in 
human aortic endothelial cells (Ouchi et al. 2000). Plasma levels of adiponectin are 
decreased in subjects with obesity (Arita et al. 1999) or CHD (Ouchi et al. 1999), but 
can be increased by TZDs (Maeda et al. 2001). 
 
PPREs have been identified in several genes that are implicated in FFA 
metabolism. These include adipocyte fatty acid binding protein (aP2) (Pelton et al. 
1999), ACS (Schoonjans et al. 1995, Martin et al. 1997), FATP-1 (Martin et al. 1997, 
Motojima et al. 1998), FAT (Motojima et al. 1998) and LPL (Schoonjans et al. 1996, 
Lefebvre et al. 1997), which are all up-regulated by PPARγ activation. Increased 
expression of these genes in adipose tissue may enhance FFA trapping, lower FFA 
flux to muscle, and thus improve glucose uptake in muscle. Recently it was shown 
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that PPARγ expression in human skeletal muscle is correlated with the expression 
of FABP and LPL in the same muscle samples (Lapsys et al. 2000).  
 
2.3.3.2 Effect of PPARγ activation on serum lipid levels 
 
PPARγ affects plasma levels of TG-rich lipoproteins mainly by influencing TG 
clearance (Lefebvre et al. 1997). As mentioned above, PPARγ activation may 
enhance FFA trapping in adipose tissue by inducing several central genes involved 
in fatty acid uptake. PPARγ activation by TZDs induces LPL expression 
(Schoonjans et al. 1996, Lefebvre et al. 1997), and thus enhances lipolysis and FFA 
uptake. Interestingly, in the A-ZIP mice that completely lack white adipose tissue, 
serum TG level decreased and fatty acid oxidation increased upon TZD treatment. 
Concomitantly, the PPARγ mRNA level in the liver of the A-ZIP mice was markedly 
increased, and rosiglitazone treatment further increased the triglyceride content of 
the fatty livers (Chao et al. 2000). 
 
2.3.3.3 Regulation of PPARγ activity and expression 
 
The mechanisms that regulate PPAR activity are depicted in Figure 5. TZDs are 
synthetic ligands of PPARγ. With regard to the natural ligands/activators, a number 
of eicosanoids and fatty acids have been reported to bind to, and activate, PPARγ 
(Kliewer et al. 1997, Krey et al. 1997). The most potent naturally occurring ligand of 
PPARγ is prostaglandin J2 (Forman et al. 1995, Kliewer et al. 1995). Nisoli et al. 
(2000) infused Intralipid and heparin in nine non-obese male volunteers. The 
increased availability of FFA induced marked increases in mRNA levels of FAT, 
PPARγ2, leptin and TNF-α in subcutaneous adipose tissue from gluteal region. As 
PPARγ activation is known to suppress TNF-α expression, the authors speculated 
that the increment in TNF-α gene expression by FFA may present a mechanism 
that aims to compensate for excessive lipid accumulation (Nisoli et al. 2000). 
Another example of a molecule that is both a target gene and a regulator of PPARγ 
is leptin. Leptin treatment of rats increased adipose tissue PPARγ expression (Qian 
et al. 1998), whereas PPARγ activation reduced the expression of leptin in rat 
adipocytes (De Vos et al. 1996, Kallen and Lazar 1996). 
 
Rieusset et al. (1999) have shown that insulin acutely increases PPARγ1 and PPARγ2 
expression in human adipose tissue both in vitro and in vivo. On the other hand, 
insulin-stimulated phosphorylation of PPARγ lowers receptor activity (Hu et al. 
1996a, Adams et al. 1997). TZDs seemed, paradoxically, to lower PPARγ mRNA 
levels in 3T3-L1 adipocytes, but the expression of genes that are positively 
regulated by PPARγ such as aP2 or LPL was not reduced (Perrey et al. 2001). In 
another study on 3T3-L1 adipocytes there was no reduction in either PPARγ or aP2 
expression by TZDs (Kallen and Lazar 1996). 
 
A recent observation showed that selective retinoid X receptor agonists (rexinoids) 
can activate retinoid X receptor in the receptor heterodimer, and thus rexinoids, too, 
are involved in the transcriptional control of genes implicated in lipid metabolism 
(Mukherjee et al. 1998, Martin et al. 2000). 
 
Phosphorylation of the N-terminal domain of PPARγ2 by mitogen-activated protein 
kinase reduces the ability of PPARγ2 to bind to PPREs (Hu et al. 1996a) (Figure 5). 
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Mutations affecting this phosphorylation site may augment receptor activity leading 
to obesity (Ristow et al. 1998). Ligand binding induces conformational changes in 
PPARs that allow interaction with co-activators and release of co-repressors, as 
reviewed by Escher and Wahli (2000). Several putative cofactors of PPARγ have 
been shown to interact with PPARγ, but their importance has not been established, 
and no PPARγ specific co-activators have been identified (Auwerx 1999).  
 
2.3.4 The causes and consequences of abnormal fatty acid metabolism in 
 familial combined hyperlipidemia 
 
The elevated plasma concentration of FFA in FCHL can result from either reduced 
uptake of FFA in peripheral tissues or increased release of FFA from either 
circulating TG-rich lipoproteins or adipose tissue (Figure 1).  
 
LPL is the key enzyme that hydrolyses TG in chylomicrons and VLDL. As the 
activity of LPL in FCHL has been shown to be either normal (Reynisdottir et al. 
1997) or reduced (Babirak et al. 1992), enhanced liberation of FFA from plasma 
lipoproteins is not a likely explanation for elevated plasma FFA in FCHL. As regards 
increased mobilisation of fatty acids from adipocytes, the evidence is opposite. 
Lipolysis and HSL activity have been reported to be decreased in FCHL 
(Reynisdottir et al. 1995, Reynisdottir et al. 1997, Reynisdottir et al. 1998). Thus the 
most likely explanation is impaired fatty acid trapping by adipocytes, although this 
has not been directly verified so far.  
 
Elevated serum FFA can have several harmful consequences (Figure 6). The idea 
that elevated serum FFA levels play a major role in the development of insulin 
resistance was first introduced in 1963 by Randle et al. (1963). The key point of the 
hypothesis was that increased plasma FFA causes increased β-oxidation of fatty 
acids in muscle. An increase in intracellular acetyl-CoA and citrate concentrations 
results in decreased glucose oxidation and finally in reduced glucose uptake. Since 
then, it has been confirmed that physiological elevations of plasma FFA reduce 
peripheral insulin sensitivity both in healthy subjects and in subjects with type 2 
diabetes (Ferrannini et al. 1983, Boden et al. 1994, Boden 1996a). The effect of 
reduced insulin sensitivity is further reinforced by the stimulation of hepatic glucose 
output by FFA (Ferrannini et al. 1983, Fanelli et al. 1993, Boden et al. 1994). The 
connection between hyperinsulinemia and elevated FFA can be also explained by 
reduced hepatic clearance of insulin caused by FFA (Peiris et al. 1986, Svedberg et 
al. 1990).  
 
The effects of FFA on insulin secretion have been summarised by Boden (1996b). 
The in vitro effects of FFA on insulin secretion observed in animals proved different 
from the in vivo effects in normal human subjects, as high plasma FFA increased 
insulin secretion rate in vivo. Obese individuals who may have constantly elevated 
FFA levels may eventually lose the ability to raise insulin secretion in response to 
FFA. The suppressive effect of insulin on hepatic glucose production is then 
abolished, resulting in hyperglycemia.  
 
An elevated serum FFA level not only affects glucose and insulin homeostasis, but 
also has important consequences in lipid metabolism. As discussed in chapter 
2.2.1.1, the availability of FFA determines to a major extent the rate of hepatic VLDL 
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apoB production. In subjects exhibiting insulin resistance and elevated FFA levels, 
VLDL apoB production may not be suppressed postprandially. This leads to 
competition for LPL between chylomicrons and VLDL particles, which further 
enhances postprandial lipemia. If now FFA uptake into adipocytes is also impaired, 
LPL activity can be inhibited by locally elevated FFA levels (Peterson et al. 1990). 
Circulating FFA are directed to the liver, where they can further increase VLDL 
production. Concomitantly, FFA impair insulin sensitivity in peripheral tissues, which 
in turn hampers peripheral FFA uptake.  
 
 
Figure 6. The influence of elevated serum free fatty acids on metabolism in different 
organs. See text (chapter 2.3.4) for details. 
 
 
 
2.4 Carotid artery atherosclerosis and B-mode ultrasonography 
 
The central role of total and LDL cholesterol as risk factors for CHD has been 
clearly established (Martin et al. 1986, The Scandinavian Simvastatin Survival 
Study Group 1994, Shepherd et al. 1995). Recent evidence shows that a low level 
of serum HDL cholesterol (Gordon et al. 1989, Rubins et al. 1999) and high level of 
serum TG are also independently associated with an increased risk of CHD 
(Manninen et al. 1992, The BIP Study Group 2000). 
 
The initial atherosclerotic thickening of the arterial wall is compensated for by 
enlargement of the arterial lumen. The potential lumen area may diminish up to 
40% until the lumen diameter starts to decrease (Glagov et al. 1987). Angiography 
provides information only on the lumen diameter, not changes in the arterial wall. 
Likewise, Doppler ultrasound gives information on the flow in the vessel. Both 
methods are highly relevant in clinical practice, but can only detect the late stages of 
atherosclerosis. Nowadays arterial walls can also be examined by intravascular 
ultrasound or techniques based on computerised tomography or magnetic 
resonance imaging, but all these methods are either invasive, inconvenient for the 
patient, and/or expensive, which makes them unsuitable for population studies or 
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extensive intervention trials. B-mode ultrasonography is an inexpensive, non-
invasive method for assessing early atherosclerotic changes of the arterial wall.  
 
The method relies on visualisation of specific double-line echo patterns that have 
been shown to correspond to the intima and media layers of the arterial wall. B-
mode ultrasonography has become widely used as a surrogate end point of 
cardiovascular disease. Boissel et al. (1992) have suggested the following criteria 
for a valid surrogate end point: (1) it must be convenient (e.g. it occurs more often, 
and is easier to assess, than the clinical end point) and non-invasive, (2) the 
causality between the surrogate end point and the clinical end point should be 
established, and (3) in intervention studies an estimate of the anticipated clinical 
benefit should be deducible from the changes in the surrogate end point. As will be 
discussed below, all these conditions are met by B-mode ultrasonography with IMT 
measurement. 
 
2.4.1 Carotid artery intima-media thickness as a surrogate end point for 
  cardiovascular disease  
 
The validity of the far-wall (FW) IMT measurements has been established by 
comparing the IMT obtained by ultrasound imaging with the IMT determined by 
microscopy in pathologic evaluation (Pignoli et al. 1986, Wendelhag et al. 1991, 
Wong et al. 1993). However, the validity of near-wall (NW) measurements can be 
debated for the following reasons. It is the tissue interfaces with a sufficient 
difference in acoustic impedance that produce an echo. The anatomical location of 
a structure is defined by the leading edge (the upper edge) of the echo. Thus, 
thickness of an anatomical structure is defined as the distance between the leading 
edges of two different echoes (Figure 7). Similar double-line patterns can usually 
be seen in both the FW and the NW.  
 
 
 
 
Figure 7. A. Schematic illustration of anatomical (left) correlates of the echoes seen in B-
mode ultrasound images (right). See text (chapter 2.4.1) for explanation. B. Anatomy of the 
carotid artery. NW is the near-wall, FW the far-wall. Numbers indicate the acoustic 
interfaces as follows: 1. periadventitia-adventitia, 2. adventitia-media, 3. intima-lumen, 4. 
lumen-intima, 5. media-adventitia, and 6. adventitia-periadventitia (Bond et al. 1989, Rubba 
and Faccenda 1993). The distance between points 4 and 5 corresponds to the far-wall IMT.  
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To measure the intima-media complex in the FW, the leading edges of the lumen-
intima interface and the media-adventitia interface are visualised. In the NW, the 
intima-lumen interface is usually well defined. However, the bright echoes produced 
by the adventitia overlap the echo originating from the adventitia-media interface, 
which cannot therefore be accurately visualised (Wendelhag et al. 1991).  
 
Regardless of the physical facts mentioned above, there is data to support the use 
of NW measurements. Furberg et al. (Furberg et al. 1994a) have stated that even if 
there is a small systematic difference between NW and FW measurements, the 
progression rate of atherosclerosis does not differ between the NW and the FW. 
Furthermore, the inclusion of NW measurements markedly reduces the variability of 
progression. This in turn reduces the sample size required.  
 
The intima and media layers of the arterial wall cannot be distinguished from each 
other by ultrasound. It can therefore be argued that thickening of the intima-media 
complex does not necessarily reflect only atherosclerosis, but also fibromuscular 
hypertrophy of the arterial media.  
 
Atherosclerosis is a process that usually affects all parts of the arterial tree to some 
extent. The degree of carotid atherosclerosis has been shown to correlate with 
atherosclerosis in coronary arteries in autopsy studies (Young et al. 1960, Mitchell 
et al. 1962). Furthermore, superficial peripheral arteries, such as carotid arteries, 
are easier to image than coronary arteries. The causality between carotid artery IMT 
and clinical cardiovascular disease has been established in several prospective 
studies. The studies show that thickening of carotid artery walls predicts CHD or 
cerebrovascular disease (Salonen JT and Salonen R 1991, Bots et al. 1997, 
Chambless et al. 1997, Hodis et al. 1998, O´Leary et al. 1999). Cross-sectional 
studies have also shown a relationship between carotid artery IMT and clinically 
prevalent CHD and cerebrovascular and peripheral arterial disease (O´Leary et al. 
1992, Bots et al. 1994a, Burke et al. 1995, Allan et al. 1997). A strong relationship 
between carotid IMT and angiographic presence of CHD has been shown by a 
number of authors (Crouse et al. 1987, Craven et al. 1990, Wofford et al. 1991, 
Adams et al. 1995). 
 
Further evidence of the relationship between carotid artery IMT and cardiovascular 
disease can be obtained from studies that have shown an association between 
carotid IMT and the well-known risk factors for CHD, such as smoking, elevated 
serum TC, LDL cholesterol, TG, decreased HDL cholesterol, hypertension and age 
(Crouse et al. 1987, Tell et al. 1989, Salonen R and Salonen JT 1990, Salonen R 
and Salonen JT 1991b, Dempsey et al. 1992, O´Leary et al. 1992, Ryu et al. 1992, 
Wendelhag et al. 1992, Zanchetti et al. 1998). 
 
Both overt type 2 diabetes (Geroulakos et al. 1994b, Pujia et al. 1994, Bonora et al. 
1997a, el-Barghouti et al. 1997), and also asymptomatic hyperglycemia in non-
diabetic subjects and impaired glucose tolerance have been associated with 
thickening of carotid IMT (Yamasaki et al. 1995, Hanefeld et al. 1999a). In non-
diabetic subjects, the relationship between fasting plasma glucose and IMT has 
been weak or non-existent (Temelkova-Kurktschiev et al. 1998, Zanchetti et al. 
1998, Hanefeld et al. 1999b). 
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With regard to the CHD risk factors typical of FCHL, postprandial triglycerides and 
remnant lipoproteins have been shown to be related to carotid IMT in healthy 
subjects, independent of fasting TG (Ryu et al. 1992, Sharrett et al. 1995, Karpe et 
al. 1998, Boquist et al. 1999, Karpe et al. 2001). Decreased insulin 
sensitivity/hyperinsulinemia has also been associated with carotid artery wall 
thickness (Folsom et al. 1994, Agewall et al. 1995, Howard et al. 1996, Bonora et al. 
1997b, Hedblad et al. 2000, Bokemark et al. 2001). However, as Hedblad et al. 
(2000) speculated, this association may be due to covariance with other, 
established risk factors for CHD. LDL particle size was associated with the 
occurrence of moderate to large carotid artery plaques in subjects with insulin 
resistance (Hulthe et al. 1999) and with common carotid artery (CCA) IMT in healthy 
middle-aged men (Skoglund-Andersson et al. 1999), but there was no association 
between carotid artery IMT and LDL particle size in hypercholesterolemic subjects 
(Hulthe et al. 2000). 
 
Associations between carotid IMT and some of the more novel CHD risk factors 
have also been reported. Carotid IMT has been shown to correlate with 
plasminogen activator inhibitor in CHD patients and healthy subjects (Salomaa et al. 
1995, Vrtovec et al. 1999), and weakly with C-reactive protein in healthy, middle-
aged women (Hak et al. 1999). 
 
The first randomised, placebo-controlled lipid-lowering study to demonstrate 
treatment benefit using carotid IMT as an end point was the Cholesterol Lowering 
Atherosclerosis Study (CLAS) (Blankenhorn et al. 1993). The rate of progression of 
carotid IMT in asymptomatic individuals was either reduced or stopped in three 
years by pravastatin treatment in the Carotid Atherosclerosis Italian Ultrasound 
Study (CAIUS) and the Kuopio Atherosclerosis Prevention Study (KAPS) (Salonen 
et al. 1995, Mercuri et al. 1996). The Asymptomatic Carotid Artery Progression 
Study (ACAPS) and the Pravastatin, Lipids, and Atherosclerosis in the Carotid 
Arteries Study (PLAC-II) showed that statin treatment reduces both the progression 
of carotid IMT and the risk of cardiovascular events in asymptomatic subjects and 
CHD patients (Furberg et al. 1994b, Crouse et al. 1995).  
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3   AIMS OF THE STUDY 
 
FCHL is a complex disorder most probably caused by the combined effect of 
several genes and environmental factors. According to one major hypothesis, most 
metabolic abnormalities observed in FCHL can be explained by disturbances in 
adipose tissue fatty acid metabolism. 
 
This work aimed to test this hypothesis by determining whether regulators of 
adipose tissue metabolism do differ between affected FCHL family members and 
their unaffected relatives or unrelated control subjects. The studies were focused on 
selected key regulators of adipose tissue fatty acid and TG metabolism. 
 
1. The serum concentration of complement C3 is elevated in subjects with 
atherosclerotic disease or dyslipidemia. The aim of Studies I and II was to 
examine whether serum C3 concentration is elevated in affected members of 
FCHL families as compared with their unaffected relatives. If it is, is there 
evidence that this is due to increased C3 production from adipocytes? 
 
2. Acylation-stimulating protein is in vitro a potent stimulator of TG synthesis. Study 
II aimed to answer the question whether plasma ASP concentration is increased 
in affected members of FCHL families as compared with their unaffected 
relatives, and whether plasma ASP concentration changes postprandially in 
FCHL subjects. 
 
3. Hormone-sensitive lipase is the key enzyme in hydrolysis of triglycerides in 
adipocytes. Study III was performed to determine whether the activity of adipose 
tissue hormone-sensitive lipase is reduced in Finnish FCHL patients, and 
whether HSL activity affects the lipid phenotype of FCHL patients. 
 
4. Peroxisome proliferator-activated receptor γ is a transcription factor that regulates 
expression of several important genes controlling fatty acid metabolism in 
adipose tissue. The aim of Study IV was to investigate whether there are 
differences in the adipose tissue gene expression of PPARγ between FCHL 
patients and normolipidemic control subjects. 
 
Should disturbances in adipose tissue metabolism prove critical for the 
development of FCHL, these alterations should be reflected in the degree of 
atherosclerosis in FCHL family members.  
 
5. Study V aimed to assess whether disturbances in adipose tissue fatty acid and 
TG metabolism, or consequently the elevated fatty acid or TG levels, are 
reflected in the degree of atherosclerosis in FCHL family members. Additionally 
the study aimed to assess how the currently used lipid criteria can identify FCHL 
family members with atherosclerotic lesions from those without. 
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4 STUDY SUBJECTS 
 
4.1 EUFAM Study 
 
The European multicenter study on familial dyslipidaemias in patients with 
premature coronary heart disease (EUFAM Study) was a European Commission 
supported project aimed at resolving the metabolic and genetic abnormalities that 
cause FCHL and other familial dyslipidemias. The purpose of the study was to 
collect and carefully characterise a large number of FCHL families in four European 
countries. All results presented in this thesis are based on the FCHL families 
identified at the Helsinki (Helsinki University Central Hospital) and Turku (Turku 
University Central Hospital) centres in Finland during the EUFAM Study that began 
in 1995, and in the preceding pilot study. Local ethics committees approved the 
study protocols of the EUFAM Study and the substudies presented in this thesis. All 
subjects gave an informed consent before participating in the study. 
 
 
4.2 Family collection  
 
A flow-chart on family collection for the EUFAM Study is shown in Figure 8. FCHL 
probands were selected from patients undergoing elective coronary angiography or 
from angiography registers. The inclusion criteria for the probands were: (1) age 30-
60 years, (2) at least 50% stenosis in at least one coronary artery as assessed by 
standard coronary angiography, or clinically verified CHD, (3) serum TC and/or TG 
≥ 90th age and gender-specific Finnish population percentile, (4) at least three 
accessible first-degree relatives, and (5) no history of type 1 diabetes mellitus, 
hepatic or renal disease, and no hypothyroidism. Familial hypercholesterolemia was 
excluded in each proband using the lymphocyte culture method (Cuthbert et al. 
1986). 
 
If the proband met the inclusion criteria and no exclusion criteria were present, all 
first-degree relatives had their serum lipid concentrations determined in the second 
phase of the study. Families with at least two affected (serum TC and/or TG ≥ 90th 
percentile) family members (excluding families presenting lipid phenotype IIA only) 
were included in the final phase of the study, in which all accessible relatives were 
examined. 
 
From each family member over 5 years of age, venous blood samples were 
collected after an overnight fast for determination of serum lipids, other biochemical 
parameters, and isolation of DNA. Study subjects older than 15 years underwent a 
2-hour OGTT. Subjects completed standard questionnaires to provide data on 
previous medical history, medication, smoking and alcohol consumption. Waist and 
hip circumferences, weight and height were recorded, and BMI calculated as kg/m2. 
Blood pressure was measured with a mercury sphygmomanometer with the subject 
in the supine position.  
 
The TC and TG percentiles utilised in the EUFAM Study for subjects older than 25 
years were derived from the FINRISK study performed in Finland in 1992 to assess 
the levels of CHD risk factors (Vartiainen et al. 1994). For subjects younger than 25 
years, the Cardiovascular Risk Factors in Young Finns study was utilised to obtain 
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corresponding fractiles (Porkka et al. 1994). Calculation of the lipid cut-off points is 
described in detail by Porkka et al. (Porkka et al. 1997). 
 
 
 
 
Figure 8. Flow-chart on family collection for the EUFAM Study in Helsinki and Turku. See 
text (chapter 4.2) for details. 
 
 
4.3 Study subjects 
 
All FCHL family members in these studies originally participated in the EUFAM 
Study. Subjects from a total of 48 FCHL families were included in the present 
studies. In each family (except for a family in which all first-degree relatives had lipid 
phenotype IV and other affected family members represented phenotype IIA, and a 
family in which first-degree relatives had phenotype IIA but phenotype IIB was seen 
in the second degree relatives) two different lipid phenotypes were represented 
among first-degree relatives or the subjects had lipid phenotype IIB. There were 
only four families in which no family member had lipid phenotype IIB. If the subject´s 
serum TC and/or TG exceeded, or was equal to the 90th age and gender-specific 
population percentile, the subject was categorised as affected (FCHL patient).  
Proband inclusion criteria +
exclusion criteria -
YESNO
Excluded First degree relatives examined 
Family criteria -
Excluded
Family criteria +
69 FCHL families
all accessible relatives examined (n=1103)
IIA
n=126
IIB
n=111
IV
n=131
735 unaffected
family members
410 spouses368 affected
family members
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In Study II only serum TG, instead of both TG and TC, was used to determine the 
affection status. This was done because ASP is expected primarily to affect FFA 
and triglyceride metabolism, and only secondarily to influence serum cholesterol 
levels. None of the study subjects used lipid lowering medication, or had interrupted 
it for four weeks before blood sample collection or fat biopsy.  
 
 
Table 1. Subject characteristics. 
 M/F 
(n) 
Age 
(years) 
BMI 
(kg/m2) 
TC 
(mmol/l) 
TG 
(mmol/l) 
ApoB 
(mg/dl) 
Study I       
Affected 10/17 39±19 25.7±4.7 6.59±1.32 2.17±1.43 126±40 
Unaffected 15/11 38±21 23.3±3.7 4.98±0.99 1.14±0.44 88±22 
       
Study II       
Affected 27/39 41±11 27.8±3.7 6.39±1.20 2.76±1.55 125±34 
Unaffected 33/51 40±13 25.1±3.6 5.76±1.21 1.31±0.55 94±26 
Fat load study       
FCHL 5/5 42±7 27.4±2.0 6.46±1.03 3.08±1.45 128±21 
Controls 5/5 41±8 27.4±2.8 4.94±0.82 1.09±0.20 85±15 
       
Study III       
FCHL 15/25 43±12 26.4±3.6 6.48±1.04 2.00±1.09 120±25 
Controls 4/8 46±7 25.1±2.2 5.36±0.41 0.95±0.21 87±13 
       
Study IV       
FCHL 16/25 41±12 27.2±4.3 6.39±0.97 1.75±0.88 111±22 
Controls 5/9 43±9 26.2±2.8 5.18±0.57 1.11±0.48 89±18 
       
Study V       
Affected 31/46 40±11 26.2±4.0 6.36±1.15 2.14±1.80 119±31 
Unaffected 26/45 41±10 24.8±3.7 5.23±0.76 1.13±0.43 84±20 
M/F, males/females.  
 
 
Study I included 53 FCHL family members from 11 FCHL families for whom data on 
serum lipid and C3 levels were available. Serum complement levels of the 27 
affected family members were compared with those of their 26 unaffected relatives. 
The affected subjects represented equally the three different lipid phenotypes IIA 
(n=10), IIB (n=8), and IV (n=9). Three unaffected and six affected subjects had type 
2 diabetes. 
 
One hundred and fifty non-diabetic members of 35 FCHL families provided data on 
fasting plasma ASP concentration and were included in Study II. Sixty-six study 
subjects had a serum TG level that exceeded the 90th age and gender-specific 
percentile, and were categorised as affected in this study. The other 84 family 
members were coded as unaffected, and were compared with the affected family 
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members. Eighteen subjects had already participated in Study I, but serum lipids 
and C3 were measured on two different occasions. 
 
Ten healthy, normoglycemic FCHL subjects (5 males and 5 females) with serum TG 
exceeding the age and gender-specific 90th percentile (lipid phenotypes IIB (n=6) or 
IV (n=4)) were included in the oral fat load study. Ten unrelated, normolipidemic 
control subjects were carefully matched for age, sex, and BMI. One female patient 
and her control subject smoked 15 cigarettes per day. One patient and her 
corresponding control subject were postmenopausal. 
 
For Study III, subcutaneous adipose tissue biopsy specimens were obtained from 
45 FCHL patients who belonged to 13 FCHL families. In addition, fat biopsy 
specimens were taken from three family members whose serum apoB exceeded 
the 90th age and gender-specific percentile. These three subjects were coded 
affected and included only in the linkage analysis when serum apoB, instead of TC 
or TG, was used as a trait. Twelve unrelated, normolipidemic subjects were also 
biopsied, and these served as a control group. These 12 subjects were either 
spouses of FCHL family members or spouses from families previously excluded 
from the EUFAM Study because of the low number of affected family members. 
Five affected subjects included in linkage analysis had type 2 diabetes. The 
subjects with diabetes were excluded from other analyses, which consequently 
comprised 40 non-diabetic affected FCHL family members (11 with phenotype IIA, 
22 with phenotype IIB, and 7 with phenotype IV) and 12 control subjects. 
 
For Study IV, an adipose tissue sample was available from 41 non-diabetic FCHL 
patients from 22 families. Fourteen unrelated, normolipidemic control subjects 
served as a control group. Seventeen FCHL patients and eight control subjects had 
already been previously biopsied for Study III.  
 
Study V. In principle, all non-diabetic members of the families collected for the 
EUFAM Study in Helsinki and Turku centres who were over 18 years of age and 
lived a reasonable distance from Helsinki were invited for carotid ultrasonography 
examination. Family members who currently used, or had regularly used, lipid 
lowering medication were excluded because the treatment might have affected their 
IMTs, and more importantly, their serum lipid levels. Moreover, most family 
members who use lipid lowering medication have CHD, and interrupting medication 
another time was considered unethical. Thus, 39 FCHL probands and 5 relatives 
with both CHD and lipid lowering medication and 11 relatives with lipid lowering 
medication but no CHD, were excluded. A total of 148 members from 39 FCHL 
families (∼ 4 subjects/family) participated in Study V. 
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5 METHODS 
 
5.1 Lipid, lipoprotein, and other analytical methods 
 
Serum TC and TG concentrations were determined with an automated Cobas Mira 
analyser (Hoffman-La Roche, Basel, Switzerland) by enzymatic methods (kits 07 
3664 3 and 07 3680 5, respectively). Serum HDL cholesterol was quantified 
enzymatically after precipitation with phosphotungstic acid and magnesium chloride 
(kit 07 2067 4, Hoffman-La Roche, Basel, Switzerland). In Studies I and III serum 
LDL cholesterol concentration was calculated using the Friedewald formula 
irrespective of serum TG concentration (serum TG exceeded 4.52 mmol/l in five 
subjects in Studies I and III). For Studies II and V LDL was separated by sequential 
flotation in an ultracentrifuge (Taskinen et al. 1988). Commercial quality control 
samples were used to standardise the measurement of lipids and apolipoproteins. 
Interassay coefficients of variation (CV) for lipid and apolipoprotein measurements 
were studied over a 12-month observation period. CVs for lipid measurements were 
2% for TC and TG and 3% for HDL cholesterol. As for lipid measurements, the 
laboratory participates in an international quality assessment scheme organised by 
Labquality (Helsinki, Finland). 
 
Serum total apoB, serum apoA-I, and apoA-II concentrations were measured by 
immunoturbidimetry (Orion Diagnostica, Espoo, Finland; kit 67249 and Boehringer-
Mannheim, Mannheim, Germany; kits 726 478 and 726 486, respectively). 
Interassay CV was 4% for apoB, apoA-I and apoA-II determinations. Commercial 
standards used for apolipoprotein assays had been calibrated against the controls 
from the Centers for Disease Control and Prevention.  
 
The OGTT was performed with a 75 g dose of glucose. Blood was drawn at 0, 30, 
60 and 120 minutes for measurement of blood glucose, serum free insulin and FFA. 
Blood glucose concentrations were measured using glucose dehydrogenase 
method (Gluc-DH, Merck Oy, Darmstadt, Germany). Serum free insulin 
concentrations were determined by radioimmunoassay using the Phadeseph Insulin 
RIA kit (Pharmacia, Uppsala, Sweden). The interassay CV of insulin measurements 
varied between 6% and 7% in low and high controls, respectively. Concentrations of 
FFA in serum were measured using the microfluorometric method of Miles et al. 
(1983). CVs over a 12-month period were 8% for the low control and 4% for the 
high control.  
 
 
5.2 Acylation-stimulating protein, C3, and C4 measurements 
 
ASP concentrations were measured from EDTA-plasma using ELISA (Quidel, San 
Diego, USA), which uses monoclonal human anti-C3a-desArg as a detecting 
antibody. Each measurement was performed in triplicate and all samples from a fat 
load test (patient and control subject) were measured in the same assay if possible. 
The inter- and intra-assay CVs were 12% and 2%, respectively. 
 
The ASP results obtained with Quidel´s ELISA kit were compared with the results 
derived using sandwich ELISA, which is used by Sniderman and Cianflone (Saleh 
et al. 1998). ASP concentrations of 73 samples (not included in the present study) 
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were determined by both methods. The Spearman´s correlation coefficient for the 
two methods was 0.59, P<0.001. 
 
Serum concentrations of C3 and C4 were determined at the Department of 
Bacteriology and Immunology, Haartman Institute, University of Helsinki, by 
nephelometry, using antibodies against C3c and C4 (Behringwerke AG, Marburg, 
Germany) and a BN-100 nephelometer (Hoechst Fennica, Helsinki, Finland). The 
interassay CVs for C3 and C4 determinations were 8% and 4%, respectively.  
 
 
5.3 Oral fat load test and density gradient ultracentrifugation 
 
The test meal was a 1000 kcal mixed meal containing 72 g of fat, 50 g of 
carbohydrates and 38 g of protein. The total amount of cholesterol was 500 mg. The 
test was started in the morning after a 12-hour fast by inserting a plastic cannula 
into the patient´s antecubital vein and by drawing the fasting blood samples. After 
consumption of the meal, blood samples were collected at 2, 3, 4, 6, 8, and 9 hours 
postprandially. The study subjects were fasted during the test and were only 
allowed to drink water until the last blood samples were taken. 
 
The density of plasma samples obtained at the various time points during the oral 
fat load test was adjusted to d=1.10 kg/l with saline. Aprotinin (50 IU/ml) and 
phenylmethylsulphonyl fluoride (1mmol/l) were added as preservatives. Four ml of 
plasma were placed in a 13.4 ml tube (Ultra-Clear, Beckman, Palo Alto, USA) and 
carefully overlayered with 3.0 ml of d=1.065 kg/l and d=1.020 kg/l, and 2.8 ml of 
d=1.006 kg/l NaCl solutions. A Beckman Optima LC ultracentrifuge with an SW40 Ti 
swinging bucket rotor was used for ultracentrifugation at 40 000 rpm at +15°C. 
Chylomicrons, representing Svedberg flotation units [Sf] >400 fraction were isolated 
and collected by aspirating the top 1.0 ml fraction after a 32-minute run. The tube 
was refilled with d=1.006 kg/l saline, and ultracentrifugation was continued under 
the same conditions for 3 h 28 min. Thereafter, large VLDL particles (VLDL1, [Sf] 
60-400) were collected as previously. Other lipid fractions were isolated as 
described elsewhere (Karpe and Hamsten 1994, Mero et al. 1998). 
 
 
5.4 Hormone-sensitive lipase activity 
 
The subjects were studied in the morning after a 12-hour fast. A subcutaneous fat 
biopsy specimen of 300-1000 mg was obtained under local anaesthesia from the 
paraumbilical region using a 14G needle and a syringe. The adipose tissue 
specimen obtained was immediately placed in saline, frozen in liquid nitrogen, and 
stored at -80°C. 
 
The assay was performed essentially as described by Fredrikson (1981) and Frayn 
(1993). Adipose tissue samples of approximately 300 mg were homogenised in 600 
µl (300 µl if less than 200 mg of adipose tissue) of a buffer containing 0.25 mol/l 
sucrose, 1 mmol/l EDTA, 1 mmol/l dithioerythritol and the protease inhibitors 
leupeptin (20 µg/ml), antipain (20 µg/ml) and pepstatine (1 µg/ml). The samples 
were then centrifuged at 12 000 rpm for 3 hours at 4°C in an Eppendorf 5403 
centrifuge. Thereafter, the fat-free infranatant was recovered for analysis of HSL 
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activity using 1(3)-mono-[3H]-oleoyl-2-O-oleylglycerol as substrate (Tornqvist et al. 
1978). The substrate was mixed with phospholipid as stabiliser, and emulsified by 
sonication within one hour before the assay. The substrate was obtained from the 
Department of Medical and Physiological Chemistry at Lund University in Sweden. 
All samples were incubated in triplicate at 37°C for 30 min. Methanol-chloroform-
heptane was used to stop the reaction. The labelled FFA were isolated by addition 
of 0.1 mmol/l potassium carbonate buffer (pH 10.5). After centrifugation for 20 min 
at 2000 rpm, an aliquot of the supernatant was collected for scintillation counting. 
One unit of enzyme activity is defined as 1 µmol of fatty acid released/min. The HSL 
activity was related to the total protein concentration of the sample, which was 
measured using BCA protein assay (Pierce, Rockford, USA). The within-run CV for 
the HSL activity assay is 7% (Reynisdottir et al. 1995). All samples of Study III were 
analysed on a single occasion. 
 
 
5.5 Quantification of adipose tissue gene expression 
 
Adipose tissue samples were obtained as described for HSL. An RNeasy total RNA 
kit (Qiagen, Courtaboeuf, France) was used to prepare total RNA from fat samples. 
RNA samples were quantified by spectrophotometry, and absorbance ratios at 
260/280 nm were between 1.7 and 2.0. The average yield of total RNA was 1.8±0.7 
µg of total RNA/100 mg adipose tissue. Total RNA samples were stored at -80°C in 
water dilution until analysed. The different mRNAs were quantified using a reverse 
transcription reaction followed by a competitive polymerase chain reaction (RT-
cPCR) (Auboeuf and Vidal 1997). The assay consists of a specific first strand cDNA 
synthesis followed by co-amplification of the reverse transcription product with 
known amounts of a DNA competitor molecule. The construction of competitor 
molecules for C3 (Dusserre et al. 2000), HSL (Laville et al. 1996), and PPARγ1 and 
PPARγ2 (Auboeuf et al. 1997) is described elsewhere. The reverse transcription 
reaction was performed from 0.1 µg of total RNA in the presence of 2.5 U of 
thermostable reverse transcriptase (Tth DNA polymerase, Promega, Charbonieres, 
France) and 15 pmol of one of the designed antisense primers, in conditions that 
ensure that all target mRNA molecules are transformed into single strand cDNA 
(Auboeuf and Vidal 1997). The sequences of the primers used are presented in 
Table 2. 
 
 
Table 2. Sequences of the primers used for the RT-cPCR in Study IV. 
Gene Sense primers Antisense primers 
C3  5´-TCCTGGACTGCTGCAACTAC-3´ 5`-AATCTCCCACGTGGTGATGG-3´
 
HSL 5´-TCTTCTGCACCAGCCACAAC-3´ 5´-AGATGGTCTGCAGGAATGGC-3´ 
PPARγ 5´-TCTCTCCGTAATGGAAGACC-3´ 5´-GCATTATGAGACATCCCCAC-3´
 
PPARγ2 5´-GCGATTCCTTCACTGATAC-3´
 
5´-TCCTGGACTGCTGCAACTAC-3´ 
 
 
For the competitive PCR reaction, the reverse transcription product was added to a 
PCR mix. The sense primers were 5´-labelled with the CY-5 fluorescent dye 
(Eurogentec, Seraing, Belgium). Four aliquots of 20 µl were transferred into 0.5 ml 
microtubes containing a different, but known, amount of the competitor in a volume 
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of 5 µl. The PCR mixture and the competitive PCR reaction have been described in 
detail (Dusserre et al. 2000). The fluorescent-labelled PCR products were 
separated in 4% polyacrylamide gel with an automated laser fluorescence DNA 
sequencer (ALFexpress, Pharmacia, Uppsala, Sweden), and analysed using 
Fragment Manager software (Pharmacia, Sweden) (Auboeuf et al. 1997). The target 
mRNAs and the competitors generate different sized PCR products, which enables 
their separation by polyacrylamide gel electrophoresis. To determine the 
concentration of the target mRNA, the logarithm of the ratio of the competitor to the 
target cDNA peak surface was plotted versus the logarithm of the amount of 
competitor added in the PCR mix. However, to correct for differences in nucleotide 
number, the ratio competitor/target was first multiplied by a correction factor 
obtained by dividing the number of base pairs in target cDNA by the number of base 
pairs in the competitor (244/229 for C3, 252/306 for HSL, 474/400 for PPARγ, and 
580/506 for PPARγ2). At the competition equivalence point (log ratio=0) the initial 
concentration of the target corresponds to the initial concentration of competitor 
added (Gilliland et al. 1990). Finally, the value obtained was multiplied by two since 
the competitor is double-stranded as opposed to single-stranded target RNA. The 
PPARγ1 mRNA expression level was obtained by subtracting the amount of PPARγ
2 mRNA from the total PPARγ mRNA level. Contamination with genomic DNA was 
excluded by performing the reverse transcription step without reverse transcriptase 
in the control samples. The interassay CV in studies performed identically to Study 
IV has been 4% to 12% (Auboeuf et al. 1997, Auboeuf and Vidal 1997). 
 
 
5.6 B-mode ultrasonography and intima-media thickness measurement 
 
Ultrasound scannings were performed with a Hewlett-Packard Image Point M2410A 
ultrasound system (Hewlett-Packard, Andover, USA) equipped with a 10 MHz linear 
array transducer. Scannings were videotaped with a Panasonic AG-MD830E PAL 
S-VHS VCR (Matsushita Electric Industrial Co., Ltd., Osaka, Japan). One physician 
(K.Y.) carried out all ultrasound examinations. During scanning, the patient´s head 
was rotated 45 degrees away (if possible) from the side being scanned in the 
supine position. Longitudinal images from three distinct projections (anterolateral, 
lateral and posterolateral) were displayed for CCA, carotid bulb (CB), and internal 
carotid artery (ICA). Scannings were focused and measurements carried out at a 
total of 28 sites: the FW and the NW of six arterial segments: right and left distal 1 
cm of CCA, CB, and proximal 1 cm of ICA. In CCA and CB all three projections 
were used, and in ICA a single angle with the best visibility was used. 
 
IMT measurements were made by a single reader at Oy Jurilab Ltd 
(www.jurilab.com). Computer analysis of ultrasound images to measure IMT was 
performed with a PC equipped with a video frame grabber interfaced to an S-VHS 
VCR. The Prosound software, developed by Robert Selzer (Caltech, Pasadena, 
USA), was used to measure the IMTs (Selzer et al. 1994). This software digitises 
the video ultrasound image, locates the interfaces, and computes the IMTs. Three 
variables are derived from each measurement: the minimum, mean and maximum 
IMT. IMT measurements from videotapes were made at a total of 28 sites 
corresponding to the 28 sites where the scanning was focused. No measurements 
were done at the sites of highly echogenic structures, which were shown as 
acoustic shadowing. All measurements were made in the diastole, assessed as the 
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phase when the lumen diameter is at its smallest and IMT at its largest. All outcome 
variables were calculated on a per subject basis. The average of all mean IMT 
measurements (mean-IMT) over 28 sites (or fewer, if measurement could not be 
performed at all 28 sites) was chosen as the primary outcome variable. Likewise, 
the average of maximum IMTs (max-IMT), the average of mean far-wall IMTs (FW-
IMT), the average of mean near-wall IMTs (NW-IMT) and the average of maximum 
IMTs for each segment (CCA-IMT, CB-IMT, ICA-IMT), were calculated as 
secondary outcome variables. 
 
Intra-sonographer variability in the scannings was estimated by scanning 16 
subjects (10% of all study subjects) twice on two different occasions within three 
weeks. The Spearman´s correlation coefficient between the mean-IMTs of the 
paired scannings was 0.927 (P<0.001), CV was 2.4%, and the absolute difference 
(mean±SD) 0.028±0.024 mm. In the three carotid artery segments the correlations 
between two max-IMT measurements ranged between 0.71 (ICA) and 0.96 (CB), 
CV was 2.8% (CCA) - 7.2% (ICA), and absolute difference (mean±SD) varied from 
0.039±0.036 mm (CCA) to 0.091±0.092 mm (ICA). To assess the intra-reader 
variability, the reader measured the scannings of 10 study subjects twice. The 
Spearman´s correlation coefficient between the mean-IMTs of the paired scannings 
was 0.997 (P<0.001), CV was 0.29%, and the absolute difference 0.003±0.005 mm. 
 
 
5.7 Statistical analyses 
 
Data are expressed as mean±SD, frequencies, or percentages. The characteristics 
of fat load study subjects are reported as median and interquartile range (Study II). 
Area under the curve (AUC) and incremental AUC calculations were performed 
using the trapezoid rule (Matthews et al. 1990). 
 
For statistical comparisons of study groups, Chi-square or Fisher´s exact test was 
used for categorical variables. The non-parametric Mann-Whitney U test was used 
for continuous variables in Study I and to compare FCHL patients and controls in 
the fat load study. Because the study subjects were obtained from a family material, 
and were related to each other, they did not fulfill the assumption of independence. 
To correct, at least partly, for the non-independence of study subjects, two-way 
analysis of variance (ANOVA) was used for statistical comparison of the groups in 
Studies II-V. Family number (which indicates belonging to a certain family and is 
identical for all members of a family) was entered as a random factor in two-way 
ANOVA. 
 
To examine correlations between variables, Spearman´s correlation coefficients 
were calculated in Study I. In Studies II, IV, and V multivariate analysis was used to 
calculate correlations and partial correlations. This enabled the use of family 
number as an independent variable, again to correct for the non-independence of 
study subjects. In the fat load study, within-group changes from baseline to 
postprandial values, and differences in the postprandial responses between the 
groups were assessed by repeated-measures ANOVA with the Greenhouse-
Geisser adjustment (Ludbrook 1994). 
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Multivariate analysis in Study V was performed with the log10-transformed mean-
IMT as the dependent variable. All variables showing a correlation (adjusted only for 
family number) with mean-IMT that was at least moderate (P<0.20), but not 
necessarily statistically significant, were chosen for the multivariate analysis. 
Variables with only a moderate association with mean-IMT were also selected, 
because although not important alone, they may be important predictors when 
examined together with other parameters (Hosmer and Lemeshow 1989). Also in 
this analysis, family number was forced into the model. A backward variable 
selection method was used. Variables were removed from the model until the best 
fitting model with the maximum adjusted multiple R2 was achieved.  
 
To assess familial correlations the FCOR program of S.A.G.E. package v. 3.1 
(S.A.G.E. 1997) was used in Studies II and III. The FCOR program performs 
correlation analyses in families taking into account the structure of the pedigrees. A 
new version of the FCOR program, FCOR2 (S.A.G.E. release 4.0 Beta 6) was 
available for Study III. The FCOR2 program is also able to assess the significance 
of the correlations. Familial correlation analyses were performed using the weight 
method ”uniform weight to pedigrees”. 
 
Linkage analysis was used in Study III to investigate whether low HSL activity is 
linked to FCHL or FCHL-related phenotype. We used the MLINK program of the 
Linkage package (Lathrop et al. 1984, Ott 1991). This program can be used to 
compute the overall likelihood of the data on two alternative assumptions: that the 
two loci or traits are linked with the given recombination fraction (θ) and that they 
are not linked. The lod score is the logarithm to the base 10 of the ratio of these two 
likelihoods. This method can also be utilised to study whether two phenotypic traits 
are linked. The penetrances of the traits studied were not known and therefore, to 
avoid problems of unknown or incomplete penetrances, an affecteds-only strategy 
was used. The affecteds-only strategy uses phenotypic information only from the 
affected individuals. The unaffected individuals are coded as unknown. Also, 
because the mode of inheritance is unknown, both dominant and recessive modes 
of inheritance for both FCHL and low HSL activity were tested. For linkage analysis, 
the prevalence of FCHL was estimated as 1-2% (Grundy et al. 1987), and a gene 
frequency of 0.6% was used for the dominant mode of inheritance and 10.95% for 
the recessive model.  
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6 RESULTS 
 
6.1 Complement C3  
 
6.1.1 Serum C3  
 
Serum C3 concentrations were measured in Studies I, II, and V. The data from the 
three studies are combined below. If the subject had participated in more than one 
study, the measurement of Study II was preferred. Only non-diabetic subjects were 
included in the current analyses. The 221 family members were divided into three 
groups according to their serum TG and TC levels. The high TG group (n=83) 
comprised subjects representing lipid phenotypes IIB and IV, while the high TC 
group (n=47) contained subjects with phenotype IIA. Family members whose TC 
and TG were both below the 90th percentile, were coded as unaffected (n=91).  
 
Mean (±SD) serum C3 levels of the family members are shown in Table 3. The 
three phenotype groups had significantly different serum C3 levels (P<0.001) 
(Table 3, Figure 9). When adjusted for BMI, the difference was still significant 
(P=0.05). In post-hoc analyses the high TG group differed from the high TC group 
(P=0.004), and the unaffected group (P<0.001). There was also a significant 
difference in mean serum C3 level between the subjects with high TC and the 
unaffected relatives (P=0.001). Men had a slightly higher average serum C3 than 
women, but the difference did not reach statistical significance (1.5±0.5 g/l vs. 1.4±
0.3 g/l, P=0.06), unless adjusted for BMI (P=0.043). 
 
 
Table 3. Subject characteristics combined from Studies I, II, and V. 
 Lipid phenotype  
 n High TG n High TC n Unaffected P-value a 
Age (years) 83 40.0±13.6 47 42.4±14.0 91 39.7±14.3 0.45 
Males/females, (% M) 83 33/50 (40)  47 20/27 (43) 91 38/53 (42) 0.94 
BMI (kg/m2) 83 27.4±4.3 b 47 24.8±3.2 91 24.7±3.8 0.02 
Waist-hip ratio 82 0.88±0.09 c 41 0.84±0.09 81 0.83±0.08 0.03 
TG (mmol/l) 83 2.64±1.52 47 1.44±0.54 d 91 1.19±0.45  
TG-max (mmol/l) 83 3.33±1.92 47 1.71±0.57 91 1.24±0.45  
TC (mmol/l) 83 6.26±1.23 47 6.72±1.10 91 5.17±0.83  
TC-max (mmol/l) 83 6.70±1.23 47 7.30±0.92 91 5.33±0.81  
ApoB (mg/dl) 83 124±34  47 114±23  89 85±20 e <0.001 
HDL-C (mmol/l) 83 1.21±0.36 b 47 1.61±0.47 91 1.53±0.42 <0.001 
Glucose (mmol/l) 82 4.6±0.6 41 4.6±0.6 85 4.3±0.5 0.17 
Insulin (mU/l) 83 10.1±4.7 b 44 6.8±3.3 89 7.0±3.4 <0.001 
C3 (g/l) 83 1.6±0.4 b 47 1.4±0.4  91 1.2±0.2 e <0.001 
ASP (ng/ml) 77 151±53 39 133±63 75 137±55 0.66 
TG-max and TC-max are the highest TG and TC values, respectively, measured for each 
subject at any visit during the EUFAM Study. HDL-C is HDL cholesterol. a Assuming all 
study subjects are independent. b P<0.01 vs. high TC group and the unaffected. c P<0.001 
vs. the unaffected, d P<0.05 vs. the unaffected, e P<0.01 vs. the high TG and high TC 
groups.  
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Figure 9. Individual serum C3 and plasma ASP concentrations shown separately for the 
three phenotype groups. P-values denote differences between the three groups. Horizontal 
lines represent the means of the groups 
 
 
 
Gender and family number-adjusted correlations between serum C3 and selected 
clinical and biochemical variables are shown in Table 4. Serum C3 values are 
plotted against serum TG and insulin-AUC values in Figure 10. Correlations with 
serum C3 were not significantly affected by adjustment for BMI (data not shown). 
 
 
 
Table 4. Gender and family number-adjusted correlations of serum C3 concentration (g/l), 
plasma ASP concentration (ng/ml), and adipose tissue C3 mRNA expression (amol/µg of 
total RNA) with selected clinical and biochemical variables. 
 Serum C3 Plasma ASP C3 mRNA 
 n r n r n r 
Age (years) 221 0.11 191 0.01 40 0.24 
BMI (kg/m2) 221 0.28 191 0.11 40   0.36 a 
Waist-hip ratio 204 0.38 190 0.16 39 0.31 
TG (mmol/l) 221 0.62 191    0.21 b 40 0.25 
TC (mmol/l) 221 0.48 191 0.10 40 0.31 
ApoB (mg/dl) 219 0.62 190 0.12 36 0.31 
HDL-C (mmol/l) 221 -0.42 191 -0.12 40 -0.07 
Glucose-AUC (mmol/l⋅h-1) 203 0.32 182 0.03 39    0.34 a 
Insulin-AUC (mU/l⋅h-1) 202 0.39 181 0.12 38    0.36 a 
FFA-AUC (µmol/l⋅h-1) 195 0.35 175 0.06 35 0.22 
C3 (g/l)     39 0.20 
ASP (ng/ml) 191 0.30   34 -0.02 
HDL-C denotes HDL cholesterol. All correlations with serum C3, except for age, were 
significant (P<0.001). a P<0.05, b P<0.01. Significance levels are reported assuming all 
study subjects are independent. 
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Familial correlations of serum C3 were calculated in Study II (see Table 4 in Study 
II). Age and gender-adjusted values obtained by calculating residuals for the traits 
were used in the analyses. A statistically significant sibling-sibling correlation for C3 
(r=0.26, P<0.01) was found in 103 sibling pairs, suggesting that serum C3 level may 
be familial. The parent-offspring correlation (r=0.15 in 54 pairs) did not reach 
statistical significance. Serum C3 correlated with TG (r=0.22, P<0.01), HDL 
cholesterol (r=-0.20, P<0.05), and FFA-AUC (r=0.24, P<0.01) in siblings. The 
parent-offspring correlations showed significant positive values between C3 and 
insulin (r=0.21, P<0.05), and BMI (r=0.21, P<0.05), and a negative correlation 
between C3 and HDL cholesterol (r=-0.32, P<0.01). These correlations imply that 
C3 may share a common genetic background with TG, HDL cholesterol, insulin, 
FFA and BMI.  
 
6.1.2 C3 gene expression in adipose tissue 
 
In Study IV, the mRNA expression level of C3 was quantified in subcutaneous 
adipose tissue of 41 affected FCHL family members and 14 normolipidemic control 
subjects. The C3 mRNA level of one FCHL subject was 86.0 amol/µg of total RNA, 
which is much more than the maximum for the other subjects (46.3 amol/µg total 
RNA). The value obtained in this sample remained identical when the measurement 
was repeated. This subject was excluded from further analyses. C3 mRNA 
expression was similar in FCHL subjects and the normolipidemic control subjects 
(20.0±9.8 vs. 19.7±9.4 amol/µg total RNA, P=1.00). No gender difference was 
observed in adipose tissue C3 mRNA expression (P=0.40). 
 
The gender and family number-adjusted correlations between adipose tissue C3 
mRNA levels and selected FCHL-related variables in FCHL patients are shown in 
Table 4. C3 mRNA levels are plotted against serum TG and insulin-AUC values in 
Figure 10.  
 
The number of control subjects in the present study was limited, but significant 
gender-adjusted correlations between C3 mRNA expression and glucose-AUC 
(r=0.80, P=0.004) and insulin-AUC (r=0.68, P=0.02) were also seen in the control 
group. The adipose tissue C3 mRNA expression correlated relatively strongly with 
serum C3 (r=0.53) and plasma ASP (r=0.59) in controls when adjusted for gender 
but the correlations did not reach statistical significance. Adjustment for age or BMI 
did not significantly influence any of the above results. 
 
 
6.2 Acylation-stimulating protein 
 
6.2.1 Fasting plasma acylation-stimulating protein 
 
Fasting plasma ASP concentrations were measured in Studies II and V. The data 
from these two studies have been combined below, as for C3 above. Mean (±SD) 
plasma ASP levels are shown in Table 3. There were no statistically significant 
differences in mean plasma ASP levels between the three groups (P=0.66) (Figure 
9). Adjustment for BMI did not affect the results. Unlike with C3, plasma ASP level 
(mean±SD) was higher in females (150±57 ng/ml) than in males (130±53 ng/ml, 
P=0.006), regardless of BMI.  
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Gender and family number-adjusted correlations between plasma ASP and selected 
clinical and biochemical variables are shown in Table 4 (for gender, age and family 
number-adjusted correlations see Study II). The correlation between plasma ASP 
and serum TG was no longer significant if adjusted for BMI (data not shown).  
 
Figure 10. Scatter plots of serum C3, plasma ASP, and adipose tissue C3 mRNA levels vs. 
serum TG and insulin-AUC values in FCHL family members. All variables were 
logarithmically transformed and adjusted for gender and family number. Adjusted numbers 
were obtained by calculating residuals using multivariate analysis. Therefore, the scales of 
the axes do not have clinical significance. 
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Age and gender-adjusted values were used in the familial correlation analyses. A 
significant parent-offspring correlation for ASP was found (r=0.24, P<0.05). 
However, the sibling-sibling correlation for ASP was not significant (r=0.06) even 
though the number of pairs studied was higher for siblings (103 pairs) than for 
parents and offspring (55 pairs). Caution should therefore be exercised in any 
interpretation of the parent-offspring correlation. No significant familial correlations 
were observed between plasma ASP and the other FCHL-related traits. 
 
6.2.2 Postprandial plasma acylation-stimulating protein 
 
Postprandial plasma ASP concentrations were measured in 10 hypertriglyceridemic, 
unrelated FCHL patients and in 10 age, gender and BMI-matched normolipidemic 
control subjects (for subject characteristics see Table 2 in Study II). The fasting ASP 
level was higher in FCHL patients (122±25 ng/ml, range 75-164 ng/ml) than in 
control subjects (92±18 ng/ml, range 65-119 ng/ml, P=0.009). There was no 
significant postprandial change in plasma ASP in either FCHL patients (P=0.31) or 
control subjects (P=0.25), and the responses did not differ between the two groups 
(P=0.47) (Figure 11). No clear peaks were observed in postprandial ASP levels. 
Accordingly, although higher, the average incremental AUC of ASP in FCHL 
patients was not significantly different from that in control subjects (117±42 vs. 46±
51 ng/ml⋅h-1, P=0.10).  
 
TG concentration of chylomicrons increased significantly in both groups 
postprandially (P<0.001 for both groups) (Figure 11), and the response was more 
marked in FCHL patients than in control subjects (P=0.002). Serum FFA 
concentration increased significantly during the test (P<0.001 for both groups), but 
the response did not differ between the groups (P=0.29). Postprandial insulin 
response was higher in FCHL patients than in control subjects (P=0.05). 
 
 
 
Figure 11. Postprandial plasma ASP and chylomicron-TG concentrations in FCHL patients 
(black circles) and control subjects (open circles) after an oral fat load. Data points are 
means, error bars indicate standard error of mean. P-values denote differences between 
the two groups. 
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6.3 Hormone-sensitive lipase 
 
6.3.1 Hormone-sensitive lipase activity in adipose tissue 
 
Subcutaneous adipose tissue HSL activity was measured in 40 FCHL patients and 
12 normolipidemic control subjects (see Study III for subject characteristics). The 
average HSL activity (mU/mg protein) of all FCHL subjects (22±8) did not differ from 
that of the control subjects (22±7, P=0.97). HSL activity in the three phenotype 
groups (IIA, IIB and IV) averaged 23±6, 22±8 and 22±10 mU/mg protein, 
respectively, and did not differ from HSL activity in the 12 normolipidemic spouses 
(P=0.75). Adjustment for age or BMI did not significantly affect the results (data not 
shown). The individual HSL activities are shown in Figure 1 in Study III. The 
enzyme activity (mU/mg protein) in male subjects averaged 21±8 and in female 
subjects 23±8 (P=0.242).  
 
Familial correlations of adipose tissue HSL activity were calculated for 25 sibling 
pairs. A significant sibling-sibling correlation (r=0.51, P<0.01) was found, indicating 
that HSL activity may be familial. With regard to other FCHL related traits, 
significant correlations between HSL activity and TC (r=0.39, P<0.05) and waist-hip 
ratio (r=0.44, P<0.05) were found in 28 sibling pairs. No significant familial 
correlations were observed for TG, apoB, glucose, insulin or BMI. The above P-
values in familial correlation analyses were reported assuming that all pairs were 
independent.  
 
No linkage between HSL activity and FCHL was found using any of the inheritance 
patterns (see chapter 5.7 on statistical analyses). The best lod score of 1.53 (θ
=0.00) was obtained using recessive inheritance mode for both traits. No significant 
linkage could be found when linkage between HSL activity and serum TG (lod score 
1.56, θ=0.00, recessive inheritance mode used for both traits), apoB (1.27), TC 
(0.88), FFA-AUC (0.70) or lipid phenotype IIB (0.91) were examined.  
 
6.3.2 Hormone-sensitive lipase gene expression in adipose tissue 
 
Subcutaneous adipose tissue HSL mRNA expression was quantified in 40 FCHL 
patients and 14 normolipidemic control subjects. The adipose tissue HSL mRNA 
level in the FCHL patients (183±121 amol/µg total RNA) did not differ from that of 
the control subjects (213±163 amol/µg total RNA, P=0.86). There was no difference 
between HSL gene expression between men (191±120 amol/µg total RNA) and 
women (191±141 amol/µg total RNA, P=0.94). 
 
In FCHL patients, the only significant gender-adjusted correlations of HSL mRNA 
expression were observed with BMI (r=0.42, P=0.009) and waist-hip ratio (r=0.36, 
P=0.029). Seventeen FCHL subjects had data on both adipose tissue HSL activity 
and gene expression. No significant correlation was observed between these two 
parameters (r=0.11, P=0.69) when adjusted for gender. 
 
In the control subjects, HSL mRNA expression showed a significant inverse 
correlation with waist-hip ratio (r=-0.64, P=0.020) when adjusted for gender. A 
relatively high, though statistically insignificant, correlation between HSL gene 
expression and insulin-AUC was observed in control subjects when adjusted for 
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gender (r=-0.53, P=0.10). Adjustment for age or BMI did not significantly affect the 
above correlations except for the correlation between HSL mRNA level and waist-
hip ratio in control subjects, which weakened when adjusted for BMI (r=-0.44, 
P=0.14). 
 
 
6.4 PPARγ gene expression in adipose tissue 
 
In Study IV, PPARγ1 and PPARγ2 gene expression were measured from 
subcutaneous fat samples of 41 FCHL subjects and 14 normolipidemic control 
subjects. The amount of PPARγ1 mRNA was derived by subtracting the amount of 
PPARγ2 mRNA from total PPARγ mRNA.  
 
No statistically significant differences were detected between the affected FCHL 
family members and the control subjects with regard to mRNA levels of PPARγ1 (17
±8 vs. 17±6 amol/µg total RNA, P=0.63) or PPARγ2 (2.0±1.7 vs. 2.1±1.1 amol/µg 
total RNA, P=0.39). PPARγ1 gene expression was comparable in males and 
females (14±8 vs. 19±7 amol/µg total RNA, P=0.42). Women had significantly 
higher PPARγ2 gene expression in adipose tissue than men (2.4±1.6 vs. 1.4±1.3 
amol/µg total RNA, P=0.001). Adjustment for age or BMI had no significant effect on 
the differences between the groups or genders (data not shown).  
 
In FCHL patients, PPARγ1, which represents about 85% of total PPARγ, correlated 
significantly with FFA-AUC when adjusted for gender (r=0.37, P=0.03). The gender-
adjusted correlation between FFA-AUC and PPARγ2 was stronger (r=0.46, 
P=0.006) (see Figure 2 in Study IV). In control subjects, no significant correlation 
with FFA-AUC was observed for PPARγ1 or PPARγ2 mRNA (r=0.02 and r=0.06, 
respectively). Instead, PPARγ1 mRNA showed a strong negative correlation with 
TG when adjusted for gender (r=-0.87, P<0.001) (Figure 3 in Study IV), irrespective 
of age or BMI (data not shown). The correlation between PPARγ2 and TG was no 
longer significant when adjusted for gender (r=-0.28, P=0.38).  
 
 
6.5 Carotid artery intima-media thickness in familial combined hyperlipidemia 
 family members 
 
For subject characteristics, see Tables 1 and 2 in Study V. The average mean-IMT 
of all subjects was 0.74±0.14 mm. The average mean-IMT of the affected family 
members (0.75±0.15 mm) did not differ from that of the unaffected subjects (0.73±
0.13 mm, P=0.90). The result was not significantly influenced by adjustment for BMI 
or SBP (data not shown). No significant differences between the affected and 
unaffected subjects were observed in the other IMT outcome variables either (Table 
5).  
 
Because age had a significant effect on IMT, the mean-IMT was also examined in 
three age groups, each spanning approximately 15 years: 19-35, 36-50, and over 
50 years. The number of the affected and unaffected individuals was comparable in 
each age group. No significant differences in mean-IMT were observed between the 
affected and unaffected in any age group (Figure 1 in Study V).  
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Table 5. Intima-media thicknesses (mm) for the study subjects. 
 Affected 
(n=77) 
 Unaffected 
(n=71) 
 
 mean±SD range mean±SD range P-value a 
Mean-IMT  0.75±0.15 0.53-1.23 0.73±0.13 0.53-1.24 0.95 
FW-IMT  0.74±0.16 0.50-1.25 0.73±0.15 0.51-1.33 0.84 
NW-IMT 0.76±0.15 0.52-1.21 0.73±0.12 0.51-1.16 0.71 
Max-IMT 0.95±0.19 0.64-1.51 0.93±0.17 0.67-1.49 0.89 
CCA-IMT  0.89±0.15 0.63-1.49 0.87±0.13 0.70-1.21 0.91 
CB-IMT  1.04±0.28 0.63-1.94 1.02±0.24 0.62-1.97 0.76 
ICA-IMT  0.87±0.22 0.50-1.66 0.81±0.15 0.55-1.30 0.47 
Mean-IMT is the average of all mean IMT measurements over the 28 sites. FW-IMT is the 
average of all mean far-wall IMT measurements; NW-IMT, the average of all mean near-
wall IMT measurements. Max-IMT denotes the average of maximum IMTs over the 28 sites. 
CCA-IMT, CB-IMT, and ICA-IMT represent the average of maximum IMTs of the respective 
segments. a Assuming all study subjects are independent. 
 
 
There were no significant differences in mean-IMT between males (0.75±0.12 mm) 
and females (0.73±0.15 mm, P=0.26), or between smokers (current and ex-
smokers) (0.74±0.14 mm) and non-smokers (0.74±0.14 mm, P=0.19). Hypertensive 
(SBP ≥ 140 mmHg, diastolic blood pressure (DBP) ≥ 90 mmHg, or antihypertensive 
medication) subjects had higher mean-IMT (0.84±0.14 mm) than normotensive 
subjects (0.71±0.12 mm, P<0.001).  
 
For the results of the correlation analyses, see Study V. The strongest correlation 
for mean-IMT was found with age (r=0.81, P<0.001). Of the lipid and lipoprotein 
variables, mean-IMT correlated statistically significantly with TC, LDL cholesterol, 
TG and apoB. Significant correlations were also observed between mean-IMT and 
glucose-AUC, but not with insulin-AUC or FFA-AUC. Mean-IMT correlated 
significantly with the following clinical variables: BMI, waist-hip ratio, SBP, DBP, 
pulse pressure and cigarette years. When adjusted for age, most of the above 
mentioned correlations tended to decrease (see Study V). Adjustment for gender 
did not significantly influence any of the correlations presented (data not shown). 
The only significant correlation between mean-IMT and C3 or ASP was found with 
C3 when adjusted for age (r=0.19, P=0.02). 
 
In multivariate analysis the final model explained 75.4% of the variation in mean-
IMT (adjusted multiple R2=0.754). Age had by far the highest standardised 
coefficient (0.747, P<0.001), followed by log-transformed pulse pressure (0.212, 
P<0.001) and gender (-0.193, P=0.002, indicating that men had higher average 
mean-IMT than women). ApoB and waist-hip ratio did not reach statistical 
significance in the final model. ApoB correlated significantly with LDL cholesterol. 
When multivariate analysis was performed without including apoB in the original 
model, LDL cholesterol remained in the final model, but still did not reach statistical 
significance. In this model, cigarette years also contributed significantly to the 
variation in mean-IMT (data not shown).  
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7 DISCUSSION 
 
7.1 Study subjects 
 
A unique, carefully characterised FCHL family material was collected in the EUFAM 
Study. Population-derived age and gender-specific lipid percentiles were used to 
categorise FCHL family members as affected or unaffected. The maximum TC and 
TG values measured for the individual at any visit during the EUFAM Study were 
used to determine the subject´s phenotype. Lipid values at each study visit were 
used for the analyses involving other data obtained at that particular visit. It was 
therefore possible that subjects presenting lipid phenotype IIA at the first visit could 
exhibit phenotype IIB at a later visit. If the lipid values were below the 90th 
percentiles at a later visit, the subject was still considered affected. During the 
course of the EUFAM Study it was found that the study subjects tended to have 
lower lipid values at later, optional visits, than at the first study visit. This is in line 
with a recent observation in a Dutch FCHL cohort that only 74% of affected family 
members showed a constant diagnosis of FCHL over a 5-year period (Veerkamp et 
al. 2001). This change of phenotype may have resulted from the subjects becoming 
aware of their dyslipidemia, and subsequent changes in the lifestyle. It also raises 
the question of whether subjects, who, after changing their diet and losing some 
weight have significantly lower lipid values than before, are truly genetically 
affected. The combined data on subjects in Studies I, II, and V (Table 3) shows, 
however, that the affected subjects were clearly hyperlipidemic as compared with 
the unaffected relatives, and that the lipid values are comparable with those in other 
FCHL cohorts (Castro Cabezas et al. 1993b, Reymer et al. 1995, Bredie et al. 
1996), though the average TC was lower than that in the Eastern Finnish FCHL 
families (Pihlajamäki et al. 2000a).  
 
In this thesis the affected FCHL family members were compared with two different 
subject groups. The primary principle was to examine whole FCHL families, and in 
studies I, II, and V the FCHL patients were compared with their unaffected relatives. 
However, when invasive or otherwise laborious study procedures such as fat 
biopsies and density gradient ultracentrifugation were involved, this was not 
possible. This is why in Studies III and IV unrelated, normolipidemic subjects served 
as a control group. 
 
With regard to the unaffected family members, it must be noted that these subjects 
were not necessarily normolipidemic but their TC and TG levels were below the 
respective age and gender-specific 90th percentiles. If the parameters studied are 
considered representative of the corresponding metabolic abnormalities, these 
parameters should be different in the affected and the unaffected relatives. 
However, overlapping in phenotypes makes it more difficult to detect these 
differences between the affected and unaffected family members. The unrelated, 
normolipidemic control subjects were required to have lipid values not only below 
the 90th percentile, but their TC had to be below 6.0 mmol/l and TG below 1.7 
mmol/l.  
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7.2 Methods 
 
7.2.1 Quantification of adipose tissue gene expression 
 
RT-cPCR was used to quantify specific mRNAs in small samples of adipose tissue. 
This method has become widely used to detect mRNAs of relatively low expression 
levels. Northern blot and in situ hybridisation are less sensitive methods than RT-
cPCR, and they are at best only roughly quantitative. Ribonuclease protection assay 
is considered to lie between Northern blotting and RT-cPCR in sensitivity. Whether 
the RT-cPCR method really is quantitative has been debated. The major 
requirement for obtaining accurate results is that the target and the competitor are 
amplified with the same efficiency. As the amplification process is exponential, 
variations in the amplification efficiency may result in large differences in the 
quantities of the end products. Use of homologous DNA competitors and thus 
identical primers for both the target and the competitor, should minimise the 
difference in amplification efficiency. Conflicting results have been reported on the 
amplification efficiencies of target and competitor fragments. It has been shown that 
shorter fragments are amplified more efficiently than longer ones (McCulloch et al. 
1995, Hiltunen et al. 1998), whereas Auboeuf et al. (1997), Auboeuf and Vidal 
(1997), and Gilliland et al. (1990) have shown that the ratio of PCR products of the 
target and the competitor remains constant through the amplification. Thus the 
method can be regarded as at least semi-quantitative. In Study IV mRNA 
expression was not corrected for house keeping gene expression, because the 
classical reference genes are expressed at extremely high levels as compared with 
the mRNAs of interest in Study IV. Moreover, the present studies did not aim at 
comparing expression of different genes or the same genes in different tissues, and 
clear differences between the samples can be reliably detected.  
 
The efficiency of the reverse transcription step under conditions similar to those in 
Study IV has been assessed by Auboeuf and Vidal (1997). They demonstrated that 
close to 100% of RNA was transformed into cDNA during the reverse transcription 
step. The problem of reproducibility in quantifying mRNA expression depends 
significantly on the reproducibility of RNA isolation and correct measurement of the 
initial concentration of the total RNA preparation. In Study IV, RNA was isolated and 
the amount of total RNA measured from all samples on a few occasions in similar 
conditions. In assays identical to Study IV, the CV varied between 9 to 18% when 
mRNA was measured several times in certain tissue samples.  
 
The other analytical methods will be discussed under their respective chapters 
below.  
 
7.2.2 Statistical analyses 
 
Family materials pose a major challenge to statistical analyses, because the 
subjects who are related to each other do not meet the assumption of independent 
observations. However, there are no uniform rules or recommendations as to how 
to analyse this kind of data. Statistical tools developed for genetics have proved to 
be of some help, but were primarily developed for analysing genotype data. 
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In Study I the data were analysed as if the subjects were independent, since the 
problem of non-independent study subjects was only recognised as a major 
problem at around this time. In later studies family number (identical in all members 
of a certain family) was included in both the variance and multivariate analyses. 
This partly corrects for the non-independence of study subjects, but also reduces 
the power of the analyses, and cannot take into account the pedigree structure. 
 
Linkage analysis can be used to study whether two phenotypic traits are linked. The 
unknown mode of inheritance of FCHL required using both possible inheritance 
models: the recessive and the dominant (Study III). To avoid problems of unknown 
penetrance, an affecteds-only strategy was used in linkage analysis. The affected 
individuals were coded as affected with a 100% penetrance and the unaffected 
individuals as unknown. Thus, no-one in the families was coded as “healthy” and 
there was no need to estimate the penetrance in the unaffected individuals. The 
gene frequencies used in Study III were based on the report by Grundy et al. 
(Grundy et al. 1987) and were also utilised in the characterisation of the novel FCHL 
locus (Pajukanta et al. 1998).  
 
 
7.3 Serum C3 
 
Serum C3 concentrations observed in the present studies are comparable with 
those determined in other studies that have investigated the relationship between 
serum C3 and hyperlipidemia or atherosclerosis (Uza et al. 1982, Muscari et al. 
2000, Weyer et al. 2000). Age has not had a significant influence on serum C3 
levels in earlier studies either (Muscari et al. 1990, Muscari et al. 2000). No 
significant gender difference in serum C3 was found in the combined data from 
Studies I, II, and V unless adjusted for BMI. Muscari and co-workers (1990) found 
higher serum C3 levels in men than in women, whereas the difference was 
apparent only after age adjustment in a study by Weyer et al. (2000).  
 
The present data show correlations between serum C3 concentration and various 
factors related to CHD risk and/or metabolic syndrome: TG, TC, apoB, HDL 
cholesterol, glucose-AUC, insulin-AUC, FFA-AUC, BMI and waist-hip ratio. These 
results are in line with previous reports (Uza et al. 1982, Muscari et al. 1990, 
Muscari et al. 1995b, Muscari et al. 1998, Muscari et al. 2000, Weyer et al. 2000). 
The basis for these correlations is not known. Increased production of C3 may take 
place in atherosclerotic plaques, liver or adipose tissue.  
 
Atherosclerotic plaques contain complement components (Hollander et al. 1979, 
Hansson et al. 1984, Vlaicu et al. 1985b, Niculescu et al. 1987b, Niculescu et al. 
1989), complement activation takes place in arterial intima (Vlaicu et al. 1985a, 
Niculescu et al. 1987a, Niculescu et al. 1987b), and activated 
monocyte/macrophages situated in atherosclerotic vessel walls are able to secrete 
C3 (Niculescu and Rus 1999). The relationship between serum C3 and various 
CHD risk factors may therefore reflect the degree of atherosclerosis, which is 
enhanced by the CHD risk factors. Serum C3 can be compared with C-reactive 
protein, also an acute phase protein that increases in response to tissue injury and 
infection (Pepys 1981), is localised in atherosclerotic lesions (Hatanaka et al. 1995), 
and correlates with CHD mortality (Kuller et al. 1996). The lack of a correlation 
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between serum C3 and carotid artery IMT in Study V may be explained by 
uncomplicated atherosclerosis in asymptomatic study subjects as opposed to 
”vulnerable” plaques with more pronounced inflammatory processes in subjects with 
CHD.  
 
Cucuianu has shown that C3 is not the only hepatic protein that is increased in 
hyperlipidemia. Elevated serum levels of lecithin:cholesterol acyltranferase 
(Cucuainu et al. 1975), plasminogen activator inhibitor (Cucuianu et al. 1991) and 
fibronectin (Cucuianu et al. 1985) have been observed in hypertriglyceridemic and 
obese subjects. Cucuianu suggested that the factors that enhance VLDL apoB 
production may also enhance the synthesis of other proteins in the liver (Cucuianu 
1998).  
 
Muscari et al. (2000) have focused attention on insulin as a possible mediator of the 
above correlations between serum C3 and variables related to the metabolic 
syndrome. There may be common mechanisms mediated by, say, cytokines that 
enhance secretion of C3 and induce insulin resistance, which in turn is associated 
with several CHD risk factors. Results of the familial correlation analyses (Study II) 
suggest that a common set of genes may affect the serum levels of C3, TG, HDL 
cholesterol, insulin, FFA and BMI, although the effects of a common environment 
could not be estimated. The nature of the common mechanisms that putatively 
affect both serum C3 levels and lipid profiles and/or insulin resistance is not known. 
Yudkin et al. (1999) proposed that adipose tissue is a determinant of a low-level, 
chronic inflammatory state that is reflected by elevated systemic concentrations of 
cytokines such as interleukin-6, TNF-α and C-reactive protein. TNF-α is known to 
impair insulin sensitivity (Hotamisligil et al. 1994) and to modulate the acute-phase 
response (including C3 production) in the liver (Perlmutter et al. 1986, Ramadori et 
al. 1988). Whether increased C3 production by adipocytes or atherosclerotic 
plaques would be reflected in serum C3 levels is not known. Several reports have 
shown correlations between serum C3 and BMI, which supports the role of adipose 
tissue in this respect. However, most of C3 is produced in the liver.  
 
In Study IV, adipose tissue C3 mRNA expression correlated with insulin levels and 
BMI. Adipose tissue C3 mRNA expression did not differ between FCHL patients and 
control subjects. Although a 40% difference between the groups would have been 
required to detect the difference at a significance level of 0.05, there was not even a 
trend towards a difference in C3 gene expression. The effect of C3 on lipid 
metabolism is not expected to be a major one. Therefore very subtle differences in 
C3 gene expression are not likely to be reflected significantly in serum lipid levels.  
 
In summary, the origin of increased serum C3 concentration in dyslipidemia is not 
known. No compelling evidence for an increased C3 production by adipocytes was 
found, but the results of the familial correlation analysis (Study II) and adipose 
tissue C3 gene expression (Study IV) do not allow a complete exclusion of this 
hypothesis.  
 
 
 
 
 
  
59 
7.4 Plasma acylation-stimulating protein 
 
Several methods have been used to determine plasma concentrations of ASP. The 
ELISA assay (Quidel) used in Study II uses monoclonal human anti-C3a-desArg as 
detecting antibody. The average ASP level in our studies (combined from Studies II 
and V) was 142±56 ng/ml (range 52-360 ng/ml), which seems to be comparable 
with the values in studies by Weyer et al. (2000) and Charlesworth et al (1998), in 
which radioimmunoassay (Amersham) was used to detect human C3a-desArg after 
precipitation of C3. The plasma ASP concentrations reported recently by the group 
of Sniderman and Cianflone using the sandwich ELISA (Maslowska et al. 1999) are 
clearly higher than those in our study subjects. The direct comparison of the ELISA 
assay used in Studies II and V and the sandwich ELISA used by Sniderman and 
Cianflone resulted in a correlation coefficient of 0.59 (see chapter 5.2). 
 
Complement activation and rapid cleavage of C3a into C3a-desArg by plasma 
carboxypeptidases occur easily during the collection of blood samples. On some 
occasions it is therefore difficult to know whether the high ASP concentrations truly 
represent a high ASP level or only complement activation during the sample 
collection. In the present studies, an arbitrary limit of 400 ng/ml was set to exclude 
falsely high ASP concentrations. 
 
No differences in plasma ASP levels were found between the three phenotype 
groups when data from Studies II and V were combined, although the subjects with 
high TG had numerically higher plasma ASP levels than their relatives with only 
high TC or the unaffected relatives. In the literature, higher plasma ASP 
concentrations have been reported in subjects with CHD than in control subjects 
(Cianflone et al. 1997), and in obese vs. non-obese subjects (Maslowska et al. 
1999).  
 
When data from Studies II and V were combined, the only significant gender-
adjusted correlation with plasma ASP was found for serum TG. Correlations 
observed in Study II between ASP and apoB, HDL cholesterol, insulin, BMI and 
waist-hip ratio were not significant in the combined material. These results are in 
line with previous studies in which a positive relationship between plasma ASP and 
TG has been found (Cianflone et al. 1997, Maslowska et al. 1999, Weyer and 
Pratley 1999). Correlations between plasma ASP and FFA or body fat content have 
also been observed, though not as consistently as with TG (Maslowska et al. 1999, 
Weyer and Pratley 1999).  
 
There was no correlation between fasting plasma ASP and carotid artery IMT in 
Study V. As with C3, this can be explained by the lack of complicated 
atherosclerotic lesions and thus the relatively low degree of inflammation in vessel 
walls. Other explanations will be discussed below.  
 
The fat load study was the first to assess the postprandial response of peripheral 
plasma ASP in hyperlipidemic subjects. The results of the fat load study reported by 
Cianflone et al. (1989a) are not comparable with the present results because of the 
aberrantly high plasma ASP levels due to methodological problems. More recent 
reports on plasma ASP concentrations after a fatty meal have detected virtually no 
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response (Charlesworth et al. 1998) or plasma ASP levels have decreased 
postprandially (Weyer and Pratley 1999).  
 
Sniderman et al. (2000) have speculated that the partly contradictory results 
obtained on ASP deficient mice may be due to differences in insulin sensitivity: both 
ASP and insulin are required for effective FFA trapping. Insulin can in part 
compensate for the lack of ASP/impaired ASP function. Better insulin sensitivity 
may explain why ASP deficiency does not alter FFA trapping as much in female as 
in male mice (Sniderman et al. 2000). In Study II, the postprandial insulin response 
was greater in FCHL patients than in control subjects. This did not, however, cause 
a difference in postprandial ASP responses. 
 
The evidence for the existence of the ASP receptor is indirect (Cianflone et al. 
1990a, Zhang et al. 1998). The most serious criticism against the ASP pathway 
hypothesis is based on the fact that the ASP receptor has not been identified. This 
hampers the determination of the importance of the ASP pathway on lipid 
metabolism in vivo.  
 
The conclusion drawn from Study II is that even if there were changes in adipose 
tissue ASP production postprandially, they can not be detected in peripheral 
plasma. The same may be true for fasting plasma ASP levels. The opposite is true 
of C3. Serum concentrations of C3 show strong correlations with several lipid and 
related biochemical parameters, although it is not clear whether the increased 
serum C3 originates from adipose tissue, or has any relevance as regards the 
function of the ASP pathway. It is also of note that C3 is a direct gene product, 
whereas generation of ASP involves several other proteins. Peake et al. (1997) 
have actually suggested that it is the synthesis of factor B, not C3, that is the rate-
limiting step in ASP production of adipocytes. The data in this work do not contain 
information with regard to ASP function or ASP concentrations at the level of 
adipose tissue. Therefore, the hypothesis of ASP pathway as a regulator of adipose 
tissue metabolism, cannot be ruled out. 
 
 
7.5 Hormone-sensitive lipase 
 
Adipose tissue HSL activity has been reported to be reduced in two Swedish FCHL 
cohorts (Reynisdottir et al. 1995, Reynisdottir et al. 1997, Reynisdottir et al. 1998). 
As FCHL is a heterogeneous disorder, it is quite possible that different defects 
contribute to development of FCHL in different populations. Study III was performed 
to investigate whether HSL activity is reduced in subcutaneous adipose tissue of 
Finnish FCHL patients. The HSL activity of 45 Finnish FCHL patients did not differ 
from that of the 12 normolipidemic control subjects. Neither were there differences 
between the groups representing different lipid phenotypes.  
 
There are several explanations as for the contradictory results between the Finnish 
and Swedish FCHL families. Firstly, it may be that HSL activity plays a more marked 
role in FCHL in Swedish than in Finnish FCHL families, and that HSL defect may 
influence the FCHL phenotype significantly only in some families. The Swedish 
FCHL families were originally collected using the 95th percentiles of TC and TG 
(Ericsson et al. 1992), and thus the Swedish subjects may have represented a more 
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serious dyslipidemia than the Finnish subjects. The slight differences in abdominal 
obesity may also have modified the results. Methodological differences can, 
however, be ruled out, as the assays were performed using the same method in the 
same laboratory in all studies. It is the differences between the substrate batches 
that prevent comparison of absolute enzyme activities between the studies.  
 
It is known that post-translational mechanisms have a more significant effect on 
HSL activity than the transcriptional control of the HSL gene (Hellström et al. 1996, 
Reynisdottir et al. 1998, Large et al. 1999). However, in obese subjects low HSL 
activity was associated with a reduction in HSL gene expression (Large et al. 1999). 
Therefore, in order also to assess this level of HSL regulation, HSL gene expression 
was quantified in subcutaneous adipose tissue of 40 FCHL patients and 12 control 
subjects in Study IV. No differences in HSL mRNA expression between the FCHL 
and  control subjects were found. There was no significant correlation between HSL 
activity and HSL mRNA expression in the 17 subjects who had data on both 
parameters. 
 
Pajukanta and co-workers (1997) have previously excluded HSL as a major gene in 
the Finnish FCHL families, as no linkage between the HSL locus and FCHL could 
be found. The results of the linkage analysis in Study III could not completely rule 
out the linkage between HSL activity and FCHL trait, even if the result was not 
positively significant either. It is therefore possible that HSL activity has a modifying 
role in FCHL. This concept is supported by the results of the familial correlation 
analysis. 
 
The significant sibling-sibling correlation of HSL, as well as familial correlations with 
TC and waist-hip ratio, suggest that HSL activity may be familial and segregate with 
the lipid phenotype in some families. In the study by Reynisdottir et al. (Reynisdottir 
et al. 1995) HSL activity did not correlate with serum lipid levels, whereas the 
lipolysis rate was correlated with serum TG, HDL cholesterol and apoB. On the 
other hand, the function of all three β-receptors was normal in FCHL. In this work 
the lipolytic cascade was not investigated at levels other than HSL. HSL is the rate-
limiting step in lipolysis, but defects at other levels of the lipolytic cascade may 
affect FCHL phenotype. It must also be remembered that the current method 
measures only the amount of total activatable enzyme, as the phosphorylated and 
dephosphorylated forms of HSL have equal activity towards the 
monoacylmonoalkylglycerol substrate (Frayn et al. 1993). As discussed in chapter 
2.3.2.3, visceral adipocytes are more sensitive to catecholamine-induced lipolysis 
than subcutaneous adipocytes. HSL activity in visceral adipose tissue has not been 
investigated so far.  
 
 
7.6 PPARγ  
 
The relationship between PPARγ mRNA expression level in subcutaneous adipose 
tissue and serum lipid and lipoprotein levels was investigated in Study IV. No 
obvious correlations between PPARγ mRNA expression and serum lipid levels were 
observed in FCHL patients. However, a positive correlation between FFA-AUC and 
both PPARγ1 and PPARγ2 mRNAs was found in FCHL patients but not in control 
subjects. PPARγ mRNA showed a strong inverse correlation with serum TG in 
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control subjects, suggesting that effective trapping of fatty acids by adipose tissue 
may enhance maintenance of normal serum TG levels in normolipidemic subjects.  
 
Observational clinical studies on PPARγ have focused on examining the effect of 
PPARγ gene polymorphisms on serum lipids, obesity and diabetes. The Pro12Ala 
variant of exon B of PPARγ2 gene has reduced transactivation capacity in vitro, 
which may lead to less efficient transcription of the target genes (Deeb et al. 1998). 
Deeb et al. (1998) originally speculated that this would result in reduced fat mass 
accumulation and improved insulin sensitivity. The effects of the Pro12Ala variant 
on obesity and serum lipids in humans have been variable (Beamer et al. 1998, 
Deeb et al. 1998, Mori et al. 1998, Mancini et al. 1999, Ringel et al. 1999, Valve et 
al. 1999, Meirhaeghe et al. 2000, Pihlajamäki et al. 2000c, Hasstedt et al. 2001). 
Most, but not all studies have shown that the Ala-allele is associated with improved 
insulin sensitivity (Deeb et al. 1998, Mori et al. 1998, Koch et al. 1999, Pihlajamäki 
et al. 2000c, Stumvoll et al. 2001) and decreased risk of type 2 diabetes (Deeb et al. 
1998, Altshuler et al. 2000, Douglas et al. 2001). 
 
Clinical studies on the effect of PPARγ gene expression on serum lipids are few. 
Correlations between PPARγ mRNA expression and CHD risk factors have been 
reported: the association has been positive with HDL cholesterol and apoA-I, and 
negative with LDL cholesterol and apoB (Bastard et al. 1999, Krempler et al. 2000, 
Zeghari et al. 2000). Some, but not all studies have shown negative correlations 
between PPARγ gene expression and insulin resistance or fasting insulin (Auboeuf 
et al. 1997, Krempler et al. 2000, Zeghari et al. 2000). Results from studies 
investigating the relationship with obesity have been inconsistent (Auboeuf et al. 
1997, Vidal-Puig et al. 1997, Montague et al. 1998, Bastard et al. 1999, Rieusset et 
al. 1999, Krempler et al. 2000), and adipose tissue PPARγ mRNA levels have not 
been associated with type 2 diabetes (Auboeuf et al. 1997, Rieusset et al. 1999).  
 
Considering the effect of TZDs and the function of LPL, FATP-1 and ACS, an 
inverse correlation between PPARγ gene expression and FFA-AUC would have 
been expected. The positive correlation seen in FCHL patients may indicate a 
disturbance of this metabolic pathway. The reason for the lack of a correlation 
between PPARγ mRNA expression and FFA-AUC in normal subjects may lie in the 
limited number or the control subjects, and the known wide variation in serum FFA 
levels.  
 
That PPARγ mRNA expression was not strongly associated with serum lipids in 
FCHL patients is not surprising, despite the central role PPARγ plays in FFA 
metabolism. It is not known to which extent PPAR expression regulates PPAR 
activity. Furthermore, relatively little is known about the regulation of PPAR activity, 
and new mechanisms emerge continuously. It may also be that other factors 
contributing to FCHL may override the effects of PPARγ in FCHL patients. This was 
also suggested in the study by Pihlajamäki and co-workers, who reported no 
difference in the frequency of Pro12Ala variants between subjects with and without 
dyslipidemia, but this PPARγ polymorphism still seemed to modify the insulin and 
lipid levels (Pihlajamäki et al. 2000c).  
 
In summary, Study IV was of limited size, and the conclusions drawn must be 
cautious. However, even if it leaves the relationships between PPARγ mRNA levels 
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and serum lipids open, it still suggests that PPARγ may play a modifying role in 
FCHL. Whether the effect of PPARγ is mediated by its effects on energy 
homeostasis, fatty acid metabolism, or insulin resistance, requires further studies.  
 
 
7.7 Carotid artery intima-media thickness  
 
7.7.1 Scanning protocol 
 
Atherosclerotic lesions tend to occur later in the CCA than in the ICA or CB (Solberg 
et al. 1971, Salonen JT and Salonen R 1993). Combined data from ACAPS, PLAC-
II and the Multicenter Isradipine/Diuretic Atherosclerosis Study (MIDAS) showed 
that IMT was thickest in CB, followed by ICA and CCA (Furberg et al. 1994a). 
Quantitative differences in associations between cardiovascular risk factors and 
atherosclerosis at different sites in the carotid artery have been reported (Tell et al. 
1989). Salonen and Salonen have observed that in middle-aged 
hypercholesterolemic men, serum LDL cholesterol is associated more strongly with 
the CCA than with CB IMT, whereas SBP is associated more strongly with IMT in 
CB than CCA (Salonen JT and Salonen R 1994). In Study V, data from all 
segments were included in the primary outcome variable mean-IMT. This was done 
to avoid problems of multiple testing, because the number of study subjects would 
not have allowed separate analyses of the segments. 
 
CCA IMT measurement can usually be obtained from approximately 99% of 
subjects (O´Leary et al. 1992, Espeland et al. 1996), but the percentage is markedly 
lower, 67-98%, in CB or ICA (O´Leary et al. 1992, Probstfield et al. 1993, Espeland 
et al. 1996). Variability is also greater in the ICA than CB, and lowest in the CCA 
(Furberg et al. 1994a), which has raised the question of whether ICA should be 
excluded at least from progression studies (Furberg al. 1994a). As Study V was  
cross-sectional, the possibly larger variation in ICA and CB IMT measurements was 
not considered a major problem. Furthermore, when the primary outcome variable 
mean-IMT was calculated excluding ICA measurements, there was no obvious 
change in variation (0.75±0.15 mm in affected vs. 0.74±0.14 mm in unaffected 
subjects). The validity of NW measurements has already been discussed in chapter 
2.4.1. In Study V, NW measurements were included in the analysis to optimise the 
power of the study.  
 
The intra-sonographer and intra-reader variabilities in Study V are reported in 
chapter 5.6. Even though an exact comparison is hampered by differences in 
scanning protocols, the reproducibility data compare well with those reported by 
Kanters et al. (1997) in a review article: intra-sonographer variability varied between 
a mean±SD absolute difference of 0.02±0.02 and 0.66±1.13 mm, CV of 2.4% and 
10.6%, and correlation coefficient of 0.62 and 0.97. The respective figures for intra-
reader variability were 0.01±0.04 and 0.65±0.69, 3.1% and 18.3%, and 0.58 and 
1.00. The comparably low variation in repeated scannings in Study V may in part be 
due to relatively thin intima-media complexes, as the variation is known to grow with 
increasing thickness of the carotid FW IMT (Bots et al. 1994b). Furthermore, the 
study lacked between-observer variability, as there was only a single person 
carrying out the scannings and another performing the measurements. 
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7.7.2 Carotid artery intima-media thickness in familial combined  
 hyperlipidemia 
 
The aim of Study V was to assess whether alterations in regulators affecting fatty 
acid and TG metabolism are reflected in the degree of atherosclerosis in FCHL 
family members. However, when the study was planned it was anticipated that 
some of the adipose tissue key regulators studied would turn out as significant 
determinants of serum lipid levels in FCHL family members. As no such major 
determinants were found, Study V was finally focused to assess the validity of the 
currently used lipid criteria as predictors of atherosclerosis. The degree of 
atherosclerosis of asymptomatic FCHL family members has not been previously 
investigated.  
 
Family members with a history of CHD or stroke were excluded from the study for 
several reasons. First, subjects with CHD were mostly the probands of the families, 
and thus had been included in the study because they, by definition, had both CHD 
and serum lipids levels that met the EUFAM Study criteria. Secondly, subjects with 
clinical cardiovascular disease are known to represent a population with a high 
degree of atherosclerosis and thickening of carotid artery walls (Craven et al. 1990, 
Wofford et al. 1991, Burke et al. 1995). Thirdly, subjects with lipid lowering 
medication had already at least once paused their medication for the purposes of 
the EUFAM Study. It was considered unethical to pause their medication another 
time, as most of these subjects also had cardiovascular disease.  
 
The fact that there was no difference in carotid artery IMT between the affected and 
unaffected family members may naturally be due to the size of the study population. 
However, it is difficult to estimate how big a difference in IMT would be of true 
clinical significance. Also, comparison of absolute IMT values with other studies is 
difficult because of the differences in study subjects and in scanning and reading 
protocols. Two articles have reported that a common carotid artery IMT ≥ 0.85 mm 
has a 83-85% predictive value of CHD (Geroulakos et al. 1994a, Hodis et al. 1996), 
which could be an indication of a relatively low degree of atherosclerosis in the 
asymptomatic FCHL family members studied here. The lack of a difference in 
carotid IMT between the two groups could also reflect a greater CHD risk in all 
FCHL relatives compared with a normal population. However, this does not seem 
likely considering the IMT values observed in this study.  
 
The association between carotid IMT and serum lipids has been established in 
several earlier reports (Crouse et al. 1987, Salonen R and Salonen JT 1991b, 
O´Leary et al. 1992, Ryu et al. 1992). In Study V, all lipid variables studied (except 
for HDL cholesterol and apoA-I) correlated significantly with mean-IMT. One 
explanation for the lack of a correlation between carotid IMT and serum HDL 
cholesterol is that the FCHL family members did not have particularly low HDL 
cholesterol levels, and thus the effect may not have been detectable. The 
association between lipid variables and age was confirmed by attenuation of these 
correlations when adjusted for age. Age as such is not likely to cause thickening of 
the arterial wall, but its strong relationship with IMT is more probably explained by 
lifelong exposure to other CHD risk factors, such as hyperlipidemia, hypertension 
and smoking. 
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In Study V, all blood pressure variables (SBP, DBP and pulse pressure) correlated 
with mean-IMT. Again, adjustment for age weakened the correlations between 
blood pressure and carotid IMT. In the literature, SBP has been consistently related 
to carotid atherosclerosis, whereas DBP has not, or the relationship has been 
negative or J-shaped (Salonen R and Salonen JT 1991a, O´Leary et al. 1992, 
Arnett et al. 1996, Zanchetti et al. 1998, Lakka et al. 1999). Pulse pressure was 
chosen to represent the blood pressure variables in the multivariate analysis, 
because there is evidence that the pulsatile components of blood pressure are 
important risk factors for CHD, and pulse pressure may be an even better predictor 
of CHD than SBP (Franklin et al. 1997, Zanchetti et al. 1998, Lakka et al. 1999). A 
single measurement of blood pressure was performed in Study V. This may in some 
cases have led to an incorrect diagnosis of hypertension. Further bias may have 
resulted from the antihypertensive medication used by eight study subjects. 
However, it is more likely that the use of antihypertensive medication weakened the 
relationship observed between blood pressure and carotid IMT 
 
There was no significant difference in mean-IMT between smokers (current or ex-
smokers) and non-smokers. Current and ex-smokers were combined because all 
these subjects were currently or had been exposed to cigarette smoking. 
Association between smoking and carotid artery IMT has been well documented in 
literature (Crouse et al. 1987, Tell et al. 1989, Salonen R and Salonen JT 1990, 
Salonen R and Salonen JT 1991b, Dempsey and Moore 1992, O´Leary et al. 1992). 
The fact that there was no difference in mean-IMT between the two groups divided 
by smoking history may be due to the design of the study, which was not planned 
primarily to examine the effect of smoking on carotid IMT. The smoking data were 
collected through questionnaires during study visits. Cigarette years were calculated 
using the number of cigarettes smoked daily at the time of the study visit. However, 
the subjects´ smoking habits may have changed over the years. Furthermore, as is 
known to be the case for alcohol consumption, the subjects may have under-
reported the number of cigarettes they smoke daily. Even so, the correlation 
between cigarette years and mean-IMT was significant. 
 
In Study V, fasting glucose and glucose-AUC correlated significantly with mean-
IMT. When adjusted for age, only the correlation with glucose-AUC remained 
significant. This is in line with the results of Temelkova-Kurktschiev et al. (1998) 
who reported, in non-diabetic subjects, only a weak correlation between fasting 
plasma glucose and carotid IMT, which disappeared when adjusted for age and 
gender. An association between atherosclerosis and hyperinsulinemia or reduced 
insulin sensitivity has been established (Folsom et al. 1994, Agewall et al. 1995, 
Howard et al. 1996, Bonora et al. 1997b). Whether this relationship is totally 
independent of the other related risk factors such as lipids, hypertension and 
obesity, has been debated (Hedblad et al. 2000, Bokemark et al. 2001). It is 
possible that FCHL family members with impaired glucose tolerance use lipid 
lowering medication (and consequently were excluded from the study) more 
frequently than their otherwise healthy relatives. Thus, the present study may 
underestimate the association of glucose and insulin with early atherosclerotic 
changes in FCHL. 
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It was interesting that in the multivariate analysis no lipid parameter contributed 
significantly to the variation in carotid IMT, whereas age, sex and pulse pressure 
were the most important predictors of the mean-IMT. The minor influence of lipids 
on IMT in FCHL family members raises the question of whether the carotid IMT is 
an indicator of atherosclerosis, a disorder of arterial intima. The intima and media 
layers of the arterial wall cannot be distinguished from each other by ultrasound, 
and therefore it is possible that the strong association between carotid IMT and 
pulse pressure observed in this study is not solely a result of increased 
atherosclerosis, but also of fibromuscular hypertrophy of the arterial media.  
 
The only lipid/lipoprotein parameter that remained in the final model in the 
multivariate analysis was apoB, but its effect on IMT variation was not statistically 
significant. Even if apoB was excluded from the model, LDL cholesterol still did not 
contribute significantly to the variation in mean-IMT. The effect of apoB also 
seemed to override the effect of smoking history on IMT, since with apoB in the 
model, cigarette years did not remain in the best model, as opposed to a model with 
no apoB. The effect of LDL cholesterol on atherosclerosis is well established, and is 
also shown in Study V by the strong correlation between LDL cholesterol and IMT. 
That apoB seemed to affect the variation in IMT even more than LDL cholesterol 
may reflect the fact that apoB is a better measure of the number of LDL particles 
than is LDL cholesterol.  
 
In summary, the IMT findings in FCHL family members indicate that the current lipid 
criteria alone are of limited value in predicting the long-term risk of cardiovascular 
disease in asymptomatic members of FCHL families. It is unlikely that identification 
of the major genes of FCHL would resolve this problem either, because FCHL is a 
heterogeneous disorder. Furthermore, the results of Study V underline the 
importance of other CHD risk factors, in addition to lipids, in the risk assessment 
and treatment of FCHL family members. 
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8 SUMMARY AND CONCLUSIONS 
 
This work examined whether selected key regulators of adipose tissue fatty acid 
and triglyceride metabolism play a central role in the pathogenesis of FCHL and 
thus can separate affected FCHL family members from their unaffected relatives or 
unrelated control subjects. Carotid artery ultrasonographic examination was carried 
out to assess the validity of the currently used lipid criteria for categorising the FCHL 
family members as affected or unaffected.  
 
Serum C3 concentration was found to be higher in FCHL family members with 
elevated serum TG than in the relatives with elevation of serum TC only, or the 
unaffected relatives. Serum C3 level correlated significantly with serum lipids and 
lipoproteins. The results of the familial correlation analyses imply that serum C3 
levels may be familial and that C3 may share a common genetic background with 
TG, HDL cholesterol, insulin, FFA and BMI. Subcutaneous adipose tissue C3 gene 
expression of FCHL patients did not differ from that of the control subjects. The 
results do not provide convincing evidence for the hypothesis that the increased 
serum C3 levels observed in FCHL are due to increased production by adipocytes, 
which would try to increase ASP formation and compensate for the potential defects 
in the ASP/C3 pathway in adipose tissue.  
 
Serum C3 concentration was not associated with carotid artery IMT in FCHL family 
members, and thus does not reflect the degree of atherosclerosis in these subjects. 
Serum C3 may be a surrogate marker of atherosclerosis through its relationship 
with various CHD risk factors.  
 
Plasma ASP concentration was no higher in affected than in unaffected FCHL 
family members. There was no significant postprandial response in plasma ASP 
after an oral fat load in FCHL patients or in normolipidemic control subjects. 
Correlations between plasma ASP and serum lipids were markedly weaker than 
those for serum C3, and in the combined data from Studies II and V there was no 
significant correlation between serum C3 and plasma ASP. This further supports the 
conclusion drawn from Study II: even if there were abnormalities in ASP 
production/function in the adipose tissue of FCHL patients, they cannot be detected 
by measuring ASP concentrations in peripheral plasma.  
 
Subcutaneous adipose tissue HSL activity or HSL gene expression was not 
reduced in Finnish FCHL patients. HSL does not have a major role in the 
pathogenesis of FCHL. However, the significant sibling-sibling correlation of HSL 
activity, as well as familial correlations with TC and waist-hip ratio, suggest that HSL 
activity may be familial and may modify the lipid phenotype in some FCHL families.  
 
PPARγ gene expression in the subcutaneous adipose tissue of FCHL patients did 
not differ from that of normolipidemic control subjects. Surprisingly, PPARγ gene 
expression correlated positively with FFA-AUC in FCHL patients. In control subjects, 
there was a strong inverse correlation between PPARγ1 expression and serum TG. 
The lack of this correlation in FCHL patients may indicate that dysfunction of 
PPARγ-regulated TG metabolism could modify serum TG levels in FCHL. 
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There was no difference in carotid artery IMT between affected and unaffected 
FCHL family members. In multivariate analysis, age, gender and pulse pressure, 
but not lipid variables, were significant predictors of carotid artery IMT in FCHL 
family members.  
 
In conclusion, the key regulators of adipose tissue fatty acid metabolism studied in 
this thesis were found not to be of major importance in the pathogenesis of FCHL. 
Future studies with novel methodology will perhaps offer an opportunity to 
investigate adipose tissue fatty acid trapping directly. The currently used lipid criteria 
alone are of limited value in predicting the long-term risk of cardiovascular disease 
in asymptomatic members of FCHL families. The results encourage the search for 
new diagnostic and prognostic criteria for FCHL. 
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